CONTENTS
About This Report 03
Strengthening Foundation,
Crafting Medicines with Care,
Cultivating Talent,
Advancing Steadily Safeguarding Health Harnessing Collective Wisdom
Chairman’s Message 04
Enhancing Governance Efficiency 14 Keeping Quality Commitments 21 Implementing Compliant Employment 42
Board of Directors’ ESG Statement 05
Strengthening Risk Management 15 Focusing on Technological Innovation 28 Empowering Employee Growth 45
About Salubris 06
Practicing Business Ethics 17 Putting Patients First 35 Unlocking Employee Potential 48
ESG Governance 09
Information Security and Privacy Protection 19 Industrial Synergy and Common Prosperity 38 Ensuring Health and Safety 50
Greening the Future,
Serving Society,
Fostering Ecological Harmony Enriching Lives
Appendix 75
Responding to Climate Change 55 Deepening Inclusive Healthcare 70
Strengthening Environmental Management 59 Building a Better Society Together 73
Practicing Resource Conservation 60
Promoting Green Operations 66
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 03
About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris
About This Report
This report is the first Environmental, Social and Governance (ESG) Report released by Shenzhen Salubris Pharmaceuticals Co., Ltd. ("Salubris," "the Company," or "We").
Adhering to the principles of objectivity, standardization, transparency, and comprehensiveness, this report details Salubris' practices and performance in the fields of ESG
and sustainable development.
Balance: This report objectively discloses positive and negative information,
| Reporting Scope
avoiding selections, omissions, or presentation formats that might inappropriately
Organizational Scope: Unless otherwise specified, the organizational scope of affect the decision-making or judgment of readers.
disclosure in this report includes Shenzhen Salubris Pharmaceuticals Co., Ltd. and its Consistency: Unless otherwise specified, the data disclosed in this report are for
subsidiaries within the scope of financial statement consolidation. 2025. We will adopt consistent statistical methods to compile the report based on
actual management conditions. Unless otherwise specified, the data disclosed in
Reporting Period: Unless otherwise specified, this report covers the period from
this report are statistically compiled according to the unified information collection
January 1, 2025, to December 31, 2025.
process and mechanism established by our company to ensure comparability.
| Basis of Preparation
| Data Sources
This report is prepared in accordance with Self-Regulatory Guidelines No. 17 for
The information and data cited in this report originates from official company
Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial
documents, statistical reports, and relevant public sources. Unless otherwise
Implementation) and the Self-Regulatory Guidance No. 3 for Companies Listed
specified, the currency unit used in the report is Renminbi Yuan(RMB).
on Shenzhen Stock Exchange—Preparation of Sustainability Report (2026 Revised
Version). It is also prepared with reference to the Environmental, Social and
Governance Reporting Code ("ESG Code") as set out in Appendix C2 to the Rules
| Report Access
Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
and the Global Reporting Initiative (GRI) Standards, to ensure readiness for future This report is compiled in both Chinese and English. If there are discrepancies
compliance with relevant HKEX requirements. between the two versions, the Chinese version shall prevail. Readers can browse or
download this report online via the following URLs:
| Reporting Principles Salubris Official Website: https://www.salubris.com/
Shenzhen Stock Exchange Website: https://www.szse.cn
Materiality: We attach great importance to the impact of environmental, social,
and governance matters on various stakeholders. This year, Salubris conducted a If you have any questions or suggestions regarding the content of this report,
materiality assessment and responded to and disclosed material ESG issues in this please feel free to contact us by phone or letter.
report. Hotline: 0755-83867888 Email: investor@salubris.com
Quantitative: This report discloses quantitative data in environmental, social and
governance categories to demonstrate our performance in key ESG indicators.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 04
About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris
Chairman’s Message
as we accelerated our transformation Safeguard Life and Health. "zero casualties, zero occupational Well-being.
through innovation and embarked on a diseases." By leveraging digital
We regard quality as fundamental to We are dedicated to improving access
new journey. We faced the challenges of management tools and conducting
business, and have established a quality to healthcare, expanding access to high-
global pharmaceutical industry changes regular emergency drills, we continue
management system throughout the quality medicines for more patients through
and the era's sustainability proposition. to enhance our risk prevention and
entire lifecycle of drugs. From raw material fair pricing strategies and broader access
We consistently adhered to the mission control and emergency response
procurement to finished product delivery, to medicines at the grassroots level. In
of "improving patients' lives through capabilities. During the reporting
every stage is subject to rigorous quality the field of public welfare and charity, the
exceptional medicines," integrating ESG period, there were no major casualty
controls. In the field of technological total donation amount reached RMB 27.1
concepts into corporate strategy and incidents and zero work-related
innovation, we continued to advance million, focusing on medical assistance,
operations. This year, with compliance fatalities, providing a strong safeguard
product innovation in 2025. XinChaoTuo rural revitalization, and education support.
as the foundation, innovation as the for employee health and safety,
and FuLiAn were successfully launched, We provided emergency assistance to
engine, and responsibility as the bond, building a safe and healthy working
and EnNaLuo received approval for dialysis communities affected by the earthquake
we made solid progress towards building environment for employees.
indications, further strengthening the in Myanmar by donating anti-infective
a high-quality sustainable development
core product portfolio. We focused on the Greening the Future to Advance medicines. We empower rural youth to
ecosystem.
Cardiovascular-Kidney-Metabolic (CKM) Ecological Responsibility. contribute to a more sustainable future.
Strengthening Foundation to Enable chronic disease treatment field, with Salubris always fulfills social responsibilities
Sustainable Growth. cumulative R&D investment reaching RMB We incorporated responding to with practical actions, promoting health and
We strictly followed laws and regulations,
we filed 241 new patent applications. Our setting clear carbon reduction targets,
continuously optimized our corporate
actively responding to the "Dual Looking ahead, Salubris will continue to
AI-enabled R&D systems also began to
governance structure, and built a diversified
Carbon" goals and green development deepen its focus on the CKM chronic
demonstrate tangible results. We strictly
board of directors. We constructed
concepts. Through energy structure disease treatment, with a particular
adhere to research ethics, strengthen our
a comprehensive risk management
optimization, water resource recycling, emphasis on cardiovascular and
intellectual property portfolio, and promote
system, embedding risk management
and refined waste management, cerebrovascular diseases. We are
responsible technology transfer, enabling
at the early stages of business activities committed to solidifying our position
innovative solutions to reach patients we significantly improved resource
to ensure the Company moves forward as an industry leader and leveraging
worldwide more efficiently. utilization efficiency, demonstrating
steadily in a complex and changing ESG as a key driver of high-quality
the Company’s commitment to
market environment. At the same time, we Cultivating Talent to Inspire Vitality. development. With more determined
green and low-carbon development
upheld the bottom line of business ethics, strategic discipline, more solid
We are "people-oriented," and build a safe, as a pharmaceutical manufacturer.
deepened anti-corruption and anti-unfair innovation actions, and deeper sense
equal, and diverse workplace environment. We actively practice the concept
competition mechanisms, achieved zero of responsibility, we will join hands with
We provide clear career development of circular economy, promoting
corruption incidents throughout the year, all employees, partners, and society
pathways, implement a diversified incentive packaging reduction and material
and encouraged supply chain partners to to jointly create a green, healthy,
system, and closely bind individual innovation, committed to building a
sign integrity agreements, jointly creating and beautiful sustainable future,
performance with the Company's long- beautiful future where humans and
a fair, ethical and healthy business contributing Salubris strength to the
term goals. In terms of occupational health nature coexist in harmony.
environment. cause of human health.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 05
About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris
Board of Directors’ ESG Statement
The Board fully recognizes the strategic value of ESG and
fully understands the impact of various ESG issues on the
Company’s sustainable development and long-term value
creation, and is committed to fully integrating sustainable
development goals into corporate strategy and daily
operations. The Company is gradually incorporating ESG
concepts and standards into corporate governance and
operational management systems in accordance with
relevant regulatory requirements and ESG guidelines.
The Company has gradually established a three-level
ESG governance structure consisting of the Governance,
Management, and Execution Levels, providing a robust
organizational framework for ESG management. The Board
is the highest decision-making body and Governance
Level for ESG matters, with key responsibilities including
formulating ESG strategies and goals, reviewing and
confirming the assessment results of major risks and
opportunities, supervising the management of material
ESG-related risks and opportunities and the progress
toward ESG targets on an annual basis, and deliberating
the Company’s ESG policies and ESG reports. Meanwhile,
the Board pays close attention to stakeholder expectations,
values the scientific rigor and rationality of the materiality
assessment process, and optimizes ESG strategic goals
and management measures based on the assessment
results of material issues to effectively address and fulfill
stakeholder expectations.
This report was reviewed and approved by the Board
before release, detailing our ESG governance, materiality
identification processes, implementation of management
practices, and key performance indicators.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 06
About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris
About Salubris
Company Overview
Founded in 1998, Salubris listed on the Shenzhen Stock Exchange in 2009 (Stock hypertension; EnNaLuo for renal anemia; and XinLiTing for type 2 diabetes. All
Code: 002294). Rooted in China and serving global markets, we are an innovative, have been included in China’s National Reimbursement Drug List (NRDL). We have
globally oriented pharmaceutical company integrating research and development successively undertaken or participated in more than 70 2 major national science
(R&D), manufacturing, and commercialization. and technology programs, as well as major national, provincial, and municipal
science and technology projects, and have been awarded the China Patent Gold
We remain committed to our mission of "Improving patients' lives through
Award 3 times 3.
exceptional medicines." With a focus on CKM chronic diseases, particularly
cardiovascular and cerebrovascular conditions, we are dedicated to safeguarding
life and health. We have established 5 innovative drug R&D centers and 3 medical
device R&D bases worldwide, and built innovation platforms covering small Corporate Philosophy
molecules, biologics and antibodies, peptides and cyclic peptides, siRNA and other
small nucleic acid therapeutics, in vivo gene editing, AI-driven drug discovery
(AIDD), and medical devices. Through continuous innovation and breakthroughs,
we strive to address unmet clinical needs.
Putting patients first and taking innovative pharmaceuticals and medical devices
as our strategic focus, Salubris has developed a globally competitive R&D pipeline
of more than 100 products in the CKM chronic disease area. 6 innovative drugs
have been launched, including XinLiTan, XinChaoTuo, FuLiTan, and FuLiAn for
Mission Vision Values
Improving patients' Becoming China's most Goodness begins with
lives through influential innovative integrity
exceptional medicines pharmaceutical company Putting patients first
pharmaceutical companies in terms of the number of marketed products with patents still in force and innovative drug with a global presence Building a culture of striving
candidates in development in the CKM therapeutic area.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 07
About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris
Major Milestones
■? Salubris was established. ■? TaiJia was launched. ■? Listed on Shenzhen Stock Exchange ■? XinLiTan, China’s first Category 1.1
(Stock Code: 002294). innovative antihypertensive drug,
was launched.
■? XinFuTai, our first ■? XinLiTan's compound patent ■? Accelerated internationalization; Salubris ■? TaiJia's formulation patent was
biologic, was approved was awarded a gold medal at Biotherapeutics, Inc. was established in awarded a gold medal at the 17th
by the NMPA. the 20th China Patent Awards. Maryland, USA. China Patent Awards.
■? FuLiTan, China’s first domestically developed ■? XinChaoTuo, China’s first domestically
fixed-dose combination of an ARB (angiotensin developed co-crystal drug in the ARNI
II receptor blocker) and a CCB (calcium class, was approved.
channel blocker), was approved for marketing.
■? Maurora Rapamycin ■? EnNaLuo was approved ■? FuLiAn, China’s first fixed-dose
Drug-Eluting Vertebral and launched. ■? XinLiTing, a domestically developed Category 1 combination antihypertensive drug
Artery Stent System was innovative drug for the treatment of metabolic comprising an ARB and a thiazide-like
approved. diseases, was approved and launched. diuretic, was approved.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 08
About This Report Chairman’s Message Board of Directors’ ESG Statement About Salubris
Strengthening Foundation, Advancing Steadily Cultivating Talent, Harnessing Collective Wisdom
■? Held 9 Board meetings with a director attendance rate of 100% ■? Annual training coverage rate reached 100%, with average training
hours per employee at 59 hours
■? 0 corruption incidents occurred, nor were any financial losses caused
by such violations
■? 0 major incidents of employee and contractor casualties or occupational
diseases occurred
■? Completed 2 information security audits; OA system completed the
registration and evaluation for Level 2 of the Multi-Level Protection Greening the Future, Fostering Ecological Harmony
Scheme (MLPS)
■? Passed ISO 14001 Environmental Management System certification
Crafting Medicines with Care, Safeguarding Health
■? Photovoltaic projects cumulatively generated 3.39 million
kWh of clean electricity, reducing carbon dioxide emissions by
approximately 1,820 tonnes
■? Commercialized Product Release Pass Rate was 100%, ■? 0 major accidents violating environmental laws and regulations and major
Market Sampling Inspection Pass Rate was 100%
environmental pollution accidents
■? Total number of product recalls for quality reasons was 0
Serving Society, Enriching Lives
■? In the hypertension field, successfully launched 4 new drugs
R&D investment amounted to RMB 1.266 billion, accounting for
A total of 32 marketed drugs were included in the NRDL
■?
■?
■? Total charitable donations reached RMB 27.1 million, including
Filed 241 patent applications, obtained 63 patent grants, maintained
cumulative public welfare drugs valued at approximately RMB 7.18
■?
a cumulative total of 392 valid patent grants
million; approximately 200 employees and volunteers participated in
■? Customer complaint processing rate was 100% volunteer services, contributing a total of 1,965 service hours
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 09
ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment
ESG Governance
Salubris upholds the concept of sustainable development, constructing and
continuously improving an ESG governance system aligned with development
strategy and business operations, promoting the comprehensive integration Salubris ESG Three-Level Governance Structure
of ESG management into strategic planning and daily operations. The
Company establishes a diversified stakeholder communication mechanism,
fully assesses the financial and impact materiality of sustainable development
issues, integrates feedback from stakeholders into business decisions, and Board of Directors
continuously optimizes sustainable development management mechanisms.
■? Lead and oversee ESG matters, focus on stakeholder expectations
■? Deliberate and approve ESG strategies, short/medium/long-term goals,
Governance
and core management systems
Level
■? Review and approve annual ESG reports and disclosure content of major
ESG issues
Heads of various business and functional departments,
coordinated by the Production Center
■? Promote the implementation of ESG plans and coordinate across
Management
departments
Level
■? Formulate ESG strategies, short/medium/long-term goals, and report to
ESG Governance Structure the Board
Salubris designates the Board as the highest decision-making body ■? Coordinate ESG data collection and data management across
for ESG governance and constructs a three-level ESG governance departments
structure consisting of the Governance Level, Management Level,
and Execution Level. The Company clarifies the composition of each
level and implements ESG responsibilities hierarchically, ensuring ESG
management is integrated into the Company's operational system and
Various business and functional departments
long-term development strategy. Additionally, the Board establishes an
Audit Committee under its oversight, granting it independent supervision
functions to ensure sustainable development work proceeds in an orderly Execution ■? Integrate ESG goals into daily work, specifically implement sustainable
manner and operations remain compliant. Level development initiatives in their respective fields
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 10
ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment
ESG Strategy and Risk
Management
Salubris possesses deep insight into throughout the entire cycle of R&D
industry trends, carrying out double and innovation, quality management,
materiality assessments based on talent development, and brand
ESG guidelines, industry surveys, and building. Stakeholder Engagement
stakeholder feedback to identify The Company attaches great importance to continuous
company material issues and Furthermore, we comprehensively
incorporate the identification of communication and positive engagement with stakeholders,
sustainable development directions, regarding it as an important foundation for improving corporate
integrating sustainable development sustainability-related risks and
opportunities into the Company's risk governance and ESG management. Through diverse and regular
concepts into corporate strategic engagement mechanisms, we maintain open channels for
planning. We always practice patient- management workflow, continuously
monitoring and managing ESG risks stakeholder feedback and actively respond to their concerns.
centricity, firmly fulfill the sustainable Combining industry and operational realities, we identify and
development responsibility of through three lines of defense, and
establish a sustainable development maintain a stakeholder list, incorporate stakeholder expectations
pharmaceutical enterprises, delve into ESG decision-making, clarify sustainable development
into the CKM chronic disease field, goal system to ensure the effective
implementation of ESG strategies in priorities, and dynamically optimize management strategies.
build a strong product portfolio, and
commit to embedding environmental, all aspects of company management
social, and governance requirements and development.
Salubris Stakeholder Communication Mechanism
Stakeholders Key Focus Issues Channels of communication
■? Emissions and waste management ■? Responding to climate ■? Risk management ■? Regular reporting ■? Participation in
■? Environmental management and change ■? Corporate governance ■? Site visits meetings/seminars
Government & ecological protection ■? Business ethics and
Regulators anti-corruption
■? Responding to climate change ■? Business ethics and ■? Corporate governance ■? Shareholders' meeting ■? Reception of visitors
■? Product R&D and innovation anti-corruption ■? Stakeholder engagement ■? Announcements ■? Phone calls
■? Sustainable supply chain ■? Risk management ■? Performance roadshows
Shareholders &
Investors
■? Product R&D and innovation ■? Customer service and ■? Access to healthcare ■? Customer satisfaction ■? Customer feedback
■? Product quality and safety rights ■? Patient health and safety survey
Customers & ■? Information security ■? Responsible marketing ■? Business communication
Consumers and privacy protection
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 11
ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment
Stakeholders Key Focus Topics Channels of communication
■? Resource management ■? Employee training and ■? Risk management ■? Board meetings ■? Daily operational
■? Responding to climate change development ■? Corporate governance management meetings
■? Product R&D and innovation ■? Business ethics and
Directors & Senior ■? Information security and privacy anti-corruption
Management protection
■? Occupational health and safety ■? Employee rights ■? Information security and ■? Employee representative ■? Suggestion boxes
■? Employee compensation and ■? Employee training and privacy protection congress ■? Roundtable discussions
benefits development ■? Employee satisfaction
Employees surveys
■? Sustainable supply chain ■? Risk management ■? Stakeholder engagement ■? Tendering and ■? Qualification and
■? Business ethics and anti- procurement assessment
corruption ■? Thematic exchange ■? Site visits
Suppliers
■? Product R&D and innovation ■? Business ethics and ■? Stakeholder engagement ■? Regular communication ■? Meetings, phone calls
■? Sustainable supply chain anti-corruption and exchange and correspondence
■? Risk management
Partners
■? Resource management ■? Public welfare ■? Patient health and safety ■? Volunteer activities ■? Health education
■? Emissions and waste management ■? Access to healthcare ■? Stakeholder engagement
■? Environmental management and
Community &
ecological protection
the Public
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 12
ESG Governance Structure ESG Strategy and Risk Management Stakeholder Engagement Double Materiality Assessment
Double Materiality Assessment Double Materiality Matrix
Salubris follows exchange guidelines and upholds the principle of double materiality.
We conducted a double materiality assessment of ESG issues in accordance with
Responding to Product R&D and Innovation*
relevant requirements of the Self-Regulatory Guidelines No. 17 for Companies Listed on Climate Change
Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation) and the High Occupational Health and Safety Product Quality
Self-Regulatory Guidance No. 3 for Companies Listed on Shenzhen Stock Exchange— and Safety*
Responsible Marketing
Preparation of Sustainability Report (2026 Revised Version), and actively respond to Access to Healthcare
stakeholder expectations. Combining industry characteristics and business realities, Emissions and Waste Management
we balance external concerns and internal impacts, comprehensively assessing the Information Security and Privacy Protection Business Ethics and Anti-Corruption
Impact Materiality
impact materiality and financial materiality of various issues. We initially identified Corporate Governance
Sustainable Supply Chain
"Product R&D and Innovation" and "Product Quality and Safety" as two key issues. After Medium
Risk Management
Patient Health and Safety
stakeholder surveys and internal cross-departmental discussions, we clarified issue Customer Service and Rights Protection
Stakeholder Engagement Employee Compensation and Benefits
priorities and completed financial materiality analysis, ultimately establishing the 2025 Employee Training and Development
Double Materiality Matrix4 5. Employee Rights
Environmental Management
and Ecological Protection Energy Management
Double Materiality Assessment Process
Low Resource Management
Public Welfare
Identify environmental, social, and governance (ESG) issues by considering policy Environmental
Issue
trends, industry characteristics, corporate strategy, and stakeholder concerns. This Social
Identification
initial screening covers 22 issues across environment, social, and governance (ESG).
Governance
Assess the actual or potential impacts generated by each issue. Comprehensively Low Medium High
Impact Materiality
consider feedback from various stakeholders to confirm the scope, duration, and
Assessment Financial Materiality
likelihood of impacts, determining the materiality level.
Financial Analyze the potential impact of ESG issues on the Company's financial
Materiality performance, operational performance, and long-term value creation, determining
Environmental Social Governance
Assessment the financial materiality level.
Issues Issues Issues
Result Synthesize the double materiality assessment results, identify priority issues for Resource Management Product R&D and Innovation* Employee Business Ethics and
Analysis and further analysis and application, and apply the assessment results to ESG strategy, Compensation and Anti-Corruption
Emissions and Waste Product Quality and Safety*
Implementation risk management, and sustainability management practices. Management Benefits Risk Management
Customer Service and Rights
Energy Management Protection Employee Rights Stakeholder
Environmental Information Security and Employee Training and Engagement
Management and Privacy Protection Development Corporate
Ecological Protection Access to Healthcare Sustainable Supply Governance
Responding to Climate Chain
related negative impacts or risks. Therefore, "Due Diligence" was not set as a material issue. Patient Health and Safety
Change Responsible Marketing
Safety Public Welfare
"Environmental Management and Ecological Protection" issue already encompasses content related to "Ecosystem and
Biodiversity Conservation" and "Environmental Compliance Management"; the "Emissions and Waste Management" issue already
encompasses content related to "Pollutant Emissions" and "Waste Management"; the "Public Welfare" issue already encompasses
content related to "Rural Revitalization" and "Social Contribution"; the "Product R&D and Innovation" issue already encompasses
content related to "Innovation-Driven Development" and "Ethics in Science and Technology"; the "Sustainable Supply Chain" issue
already encompasses content related to "Equal Treatment of small and medium-sized enterprises (SMEs)"; the "Business Ethics Note: Items marked with * represent Double Materiality Issues.
and Anti-Corruption" issue already encompasses content related to "Anti-Commercial Bribery and Anti-Corruption" and "Anti-
Unfair Competition."
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 13
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Strengthening Foundation,
Advancing Steadily
The company adheres to a compliant
business philosophy, aiming to create an
integrity-focused business environment,
and continuously deepening business
ethics supervision mechanisms. By
integrating business ethics and risk
control into strategic planning and daily
operations, we establish a comprehensive
system covering anti-corruption, fair
competition, and risk management. With
high-standard business ethics and robust
operating mechanisms, we strive to create
long-term value for stakeholders.
nor were any financial losses caused by such
number of board violations.
meetings held
times ■? Persisting in compliant operations and zero-
tolerance principle, the Company was not
involved in any corruption-related lawsuits.
■? Completed 2 information security audits;
director OA system completed the registration and
attendance rate
evaluation for Level 2 of the Multi-Level
Protection Scheme (MLPS).
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 14
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Enhancing Governance Efficiency Board Diversity
Salubris upholds the concept of board diversity. In the
Salubris regards governance efficiency as a solid guarantee for high-quality selection, nomination, and appointment of director
development, strictly following laws and regulations and regulatory requirements, candidates, we comprehensively consider gender, age,
continuously optimizing governance structure and operating mechanisms, and nationality, cultural background, educational background,
is committed to building a diverse and independent board team, enhancing professional experience, skills, race, competencies,
enterprise value, and providing solid guarantees for long-term sustainable independence, expertise, and service tenure. Meanwhile,
development. when selecting suitable candidates, we are also
committed to gradually increasing the proportion of
female directors. Director selection decisions are based
Corporate Governance on objective conditions such as their overall contribution
to business development, holistic value to the Board,
Structure alignment with succession plans and development
Salubris strictly follows the Company and perform duties according to law; directions, and their contribution to maintaining a diverse
Law of the People's Republic of China, meeting convening, holding, and Board composition, thereby continuously enhancing the
the Securities Law of the People's voting procedures comply with legal independence, professionalism, and decision-making
Republic of China and other relevant requirements. In addition, the Board has efficiency of the Board.
laws and regulations and regulatory established an Audit Committee and, as
In terms of director independence management, the
requirements, continuously improving needed, nomination, remuneration, and
Company strictly implements relevant standards, clearly
the Articles of Association and robust assessment committees. The Board is
requiring that independent non-executive directors must
governance structure, clarifying responsible for formulating working rules
maintain an independent stance and provide objective
authority boundaries, and ensuring for special committees, regulating their
opinions. During the selection process, we focus on
compliant and efficient operations. operations, and effectively improving
reviewing the independence status and relationships of
The Shareholders' Meeting, as the core the professional level and execution
candidates to ensure effective performance of duties,
decision-making body, is responsible for efficiency of Board decisions.
thereby effectively improving the oversight effectiveness
clarifying strategic directions, business
In 2025, the Group held 9 Board and decision quality of the Board, further enhancing the
objectives, and business plans, and
meetings with a director attendance fairness and transparency of corporate governance.
supervising financial and operational
rate of 100%.
performance. Directors are elected or As of the end of the reporting period, the Board had
replaced by the Shareholders' Meeting a total of 9 directors, of which 3 were independent
non-executive directors (accounting for approximately
Salubris Corporate Governance Structure
approximately 11%). The Board members possess diverse
professional backgrounds and industry experience,
Shareholders' Meeting
covering corporate governance, financial management,
human resources management, pharmaceutical
Board of Directors industry market development, and other fields. During
the reporting period, all three directors in the Audit
Remuneration and Committee and all three directors in the Nomination
Audit Committee Nomination Committee
Assessment Committee Committee were independent of management.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 15
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Strengthening Risk Management
Salubris has established a sound risk management system, clarified management
processes, and accurately identifies risks. By continuously deepening risk assessment
and response mechanisms, actively cultivating risk culture, and improving employee risk
awareness, we provide solid guarantees for the Company's steady operation.
Risk Management System
A robust risk management system is the core guarantee of the Company's long-
term stable operation. Based on guaranteeing the stability of the risk management
architecture, Salubris continuously optimizes management functions at all levels and
integrates risk management into the whole process of corporate governance and
business management. By clarifying the responsibilities of the Audit Committee, risk
management department, and front-line business departments, we effectively improve
the Company's risk management capability.
The Company establishes a risk governance architecture with three lines of defense
as the core: The first line of defense consists of various business departments,
responsible for identifying and managing risks in daily operations; The second line of
defense consists of the risk management department (Risk Control, Finance, Legal, HR
departments), responsible for formulating risk frameworks and supervising the overall
risk situation; The third line of defense is the Board Audit Committee, responsible for
auditing, evaluating, and supervising the effectiveness of risk management and internal
controls to ensure risk management capabilities align with business operations.
Salubris Three Lines of Defense
Defense Line Organization Function
First Line of Defense Front-line business departments Responsible for implementing risk identification and management in daily business activities
Risk Management Department:
Second Line of Systematically promote the identification, collection, and assessment of compliance risks, timely investigate and
Risk Control, Internal Audit,
Defense sort out potential risk points, and promote the effective operation of risk prevention and mitigation mechanisms.
Finance, Legal, HR
Conduct independent and objective audit supervision on the overall compliance management status regularly in
Third Line of Defense Board Audit Committee
accordance with the compliance system requirements
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 16
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Risk Management Process Risk Management Culture
Salubris has constructed a standardized risk management process, providing clear In terms of awareness cultivation
guidelines for risk identification, assessment, response, and monitoring, ensuring the and capability building, the
Company always maintains growth resilience and vitality in a dynamic environment. Company has constructed a regular
risk management knowledge
dissemination mechanism, integrated
risk management concepts into
Salubris Risk Management Process corporate culture and daily business
processes. The Company focused
on carrying out special training
Conduct comprehensive risk assessments, closely combining actual business operations and external environment in key areas such as compliance
Risk dynamics to determine the focus of risk control, providing solid support for formulating current and next-year risk management, R&D safety, and
Identification governance strategies. Compile and submit a comprehensive risk management review to the Company's risk information security, integrating risk
management functional department to ensure full coverage and effective management of various potential risks. awareness into the training system,
committed to enhancing the risk
sensitivity and identification accuracy
of employees at all levels, and
Various business departments rely on standardized risk classification criteria, regularly coordinating functional effectively improving the awareness of
departments at the same level to collaboratively promote the collection, identification, and in-depth analysis of risk all employees to respond to risks.
Risk
information for the next management cycle. Develop a two-dimensional risk evaluation model based on likelihood and
Assessment
potential impact to prioritize identified risks, systematically identify significant risks at the operational level, and ensure
precise, proactive risk oversight.
Deploy differentiated risk control measures based on assessment results to ensure effective governance of major risks.
Establish a risk register, compile an annual risk assessment report, and complete corresponding internal compliance
approval procedures. The assessment report needs to be submitted to the risk management functional department.
Risk Response
The formulated risk management solutions must clearly define specific goals, outline relevant management and
operational processes, and specify resource allocation requirements. Additionally, they must include a full-cycle
response strategy covering pre-event prevention, in-process control, and post-event remediation for key risk events.
To ensure major risk control measures are truly implemented, establish a continuous monitoring mechanism, generate
Dynamic special monitoring reports, and implement dynamic tracking of measure execution. Simultaneously, regularly report
Monitoring monitoring progress to the Company's senior management to ensure management remains highly attentive to major
risk prevention and control and possesses agile and efficient response capabilities.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 17
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Practicing Business Ethics
Salubris continues to standardize business operations, ensuring operational
compliance. By establishing a comprehensive anti-corruption management
system and clarifying anti-unfair competition norms, we are committed to creating
a high-quality business environment integrating compliance, integrity, and fair
competition.
Business Ethics Governance Structure
Salubris strictly follows the Criminal Law of the People's Republic of China,
the Anti-Unfair Competition Law of the People's Republic of China and the
Interim Provisions on Banning Commercial Bribery and other national laws and
regulations, formulating and implementing the Anti-Fraud Management System
for all employees. The Company continuously optimizes the business ethics
management system, clarifies employee integrity practice standards, and ensures
that business ethics construction work has solid institutional basis and execution
norms. The Company has established a business ethics governance architecture
led by the Board. Managers at all levels bear corresponding management and
leadership responsibilities according to their managed scope, ensuring the
specialization and vertical implementation of supervision duties. In addition, the
Audit Committee supervises and reviews business ethics compliance to ensure the
business ethics management system continues to run effectively.
Anti-Bribery and Anti-Corruption
To prevent fraud, strengthen corporate governance and internal control, ensure procurement, sales, finance, and human resources. By establishing clear approval
proper business conduct, and maintain the Company’s integrity in commercial mechanisms, we ensure anti-corruption measures are fully implemented in all
transactions, we comply with national laws and regulations, including the Anti- business operations. This year, no corruption incidents occurred, nor were there any
Unfair Competition Law of the People’s Republic of China and the Anti-Money financial losses incurred due to such violations.
Laundering Law of the People’s Republic of China. We also fully implement
regulatory compliance requirements, such as the Compliance Guidelines for To standardize supplier cooperation practices and develop a clean and
Pharmaceutical Enterprises on Prevention of Commercial Bribery Risks, and have transparent business ecosystem, the Company has established a strict entry
accordingly established key policies, including the Complaint and Whistleblowing mechanism. We actively require suppliers to sign the Integrity Cooperation
Policy, the Employee Handbook, and the Rewards and Disciplinary Policy. We are Agreement Commitment Letter prior to onboarding and integrate business ethics
committed to constructing a robust and perfect internal management system, guidelines and anti-corruption policy clauses into standard contracts. In the current
continuously deepening integrity governance and business ethics construction, year, over 95% of our procurement expenditure originated from suppliers whose
integrating compliance standards into key business processes such as contracts include business ethics guidelines and anti-corruption clauses.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 18
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Business Ethics Training Whistleblowing Management
Salubris is committed to enhancing employee integrity awareness, systematically Salubris strictly follows national laws and regulations, formulates the Complaint
carrying out anti-corruption training and awareness campaigns, promoting anti- Reporting System, and continuously optimizes the acceptance, investigation, and
corruption culture, and ensuring timely receipt of integrity education. The Company disposal mechanisms for petition reporting and problem clues, and is committed
continuously optimizes the business ethics training system, conducting anti-fraud to promoting relevant work towards standardization and legalization. To strengthen
training and legal, regulatory, and integrity moral education for new employees. all-staff integrity awareness, the Company carries out mandatory compliance
We carry out business ethics education for all employees annually, transforming training for new employees and key post personnel and promotes anti-bribery
regulatory norms into employees' voluntary code of conduct. Through thematic and anti-corruption policies through multiple channels such as email, internal
training and promotion, we deeply carry out business ethics and compliance networks, and meetings. In terms of the reporting mechanism, the Company
culture immersion, effectively enhancing the compliance awareness and self- establishes dedicated email addresses and internal management platforms
discipline spirit of all employees, fostering a clean and upright organizational to open and publicize reporting channels, ensuring all reporting cases receive
culture, and striving to build a distinctive integrity culture unique to the Group. timely, fair investigation and feedback. At the same time, the Company strictly
implements confidentiality, recusal, and accountability mechanisms, constructing
Business Ethics Training a comprehensive whistleblower protection system, opening anonymous reporting
Case
channels, strictly prohibiting unauthorized disclosure of reporting information,
and strictly prohibiting retaliation. This year, the Company was not involved in any
corruption-related lawsuits.
This year, Salubris focused on R&D and production key posts, organizing
special business ethics training themed "Trade Secrets." By analyzing actual
cases from various enterprises, the compliance awareness and sense of
responsibility of participants were effectively enhanced.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 19
Enhancing Governance Efficiency Strengthening Risk Management Practicing Business Ethics Information Security and Privacy Protection
Information Security and Privacy Protection
Salubris adheres strictly to the information security baseline and firmly protects individual privacy rights. The Company
continuously fortifies institutional defenses, enhances technological enablement, and cultivates organization-wide awareness,
ensuring legal compliance throughout the entire data lifecycle, thereby safeguarding business innovation and patient rights
with robust governance capabilities.
Information Security Privacy Protection
Salubris complies with laws and regulations such as the Data Security Law of the Salubris strictly complies with applicable laws and regulations in its operating
People's Republic of China and has established internal systems including the locations, such as the Personal Information Protection Law of the People's Republic
Data Compliance Management Measures, the Network and Information Security of China, and has established the Personal Information Protection Management
Management Measures and the Cybersecurity Incident Emergency Response Measures to fully safeguard the personal information of patients and trial
Disposal Measures. The Company clarifies that the Director of the Company's subjects, while strictly prohibiting any acts that infringe upon individual privacy.
Process and IT Department is responsible for leading the Company's information The Company strictly adheres to the principles of "minimum necessity" and "least
security work, comprehensively ensuring the legality and standardization of data privilege" regarding personal information collection, ensuring that information
management, and continuously improving the effectiveness of information security collection and authorization are confined to the minimum scope required
governance. for business operations, including the execution of clinical research projects,
collaboration with partner units, and research data management. At the same
The Company continues to strengthen the information security system and verifies
time, the Company fully protects the relevant individuals' rights to be informed,
its robustness through internal controls and external certifications. In 2025, the
deletion, and restriction of processing. We have also established and publicly
Company completed two information security audits; the OA system successfully
disclosed complaint and reporting channels concerning personal information
completed the registration and evaluation for Level 2 of the Multi-Level Protection
security, committing to respond to complaints within 15 working days. During the
Scheme (MLPS), confirming no major risk hazards. Meanwhile, we regularly
reporting period, no customer privacy breach incidents occurred.
conduct information security awareness promotion and specialized training for
newly hired employees, ensuring all regular employees participate in the training,
comprehensively enhancing employees' security awareness and risk prevention
skills. During the reporting period, no major information security incidents occurred
at the Company.
During the Reporting Period
number of information major information customer privacy
security audits security incidents breach incidents
occurred occurred
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 20
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Crafting Medicines with
Care, Safeguarding Health
Salubris takes product quality as the
foundation of operations and technological
innovation as the core engine. Upholding
the customer-first concept, we establish a
safe, efficient, and sustainable operational
system through enhanced quality control,
accelerating technology transfer, deepening
responsible marketing, and strengthening
supply chain ESG management, providing
solid guarantees for public health and high-
quality development.
Ensure every batch of products meets registration
standards and internal quality requirements;
commercialized product release pass rate and
rate are both 100%.
R&D investment as a percentage Quality audits encompass manufacturing sites
of annual revenue and their associated quality management
systems across multiple product categories,
including non-sterile active pharmaceutical
ingredients, tablets, and injectables.
percentage of R&D personnel
Established a management process from
complaint registration, internal collaborative
investigation to rectification feedback; product
quality complaint processing rate is 100%.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 21
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Keeping Quality Commitments | Product Quality and Safety Management Governance
Structure
Salubris regards quality as the cornerstone and commitment of development,
delving into full-lifecycle quality safeguarding. We adhere to high standards
The Company establishes an "unified leadership, hierarchical responsibility" product
and strict requirements, continuously optimizing quality management systems,
quality and safety management architecture, clarifying that the Product Quality
deepening all-staff quality awareness and agile response mechanisms,
Safety Committee coordinates, the General Manager and the Qualified Person
safeguarding public medication safety, ensuring that every product stands as a
command management, and the Qualified Person drives implementation, ensuring
solemn promise to life.
rapid response and effective resolution of drug quality safety events.
Governance Salubris Product Quality and Safety Management Governance Structure
Salubris strictly complies with local laws and regulations, continuously improving Product Quality Safety Committee
the product quality and safety management system centered on the Quality Risk
Management, the Deviation Management, the Corrective and Preventive Actions Responsible for assessing material risks, handling significant or
emergency drug incidents, making risk control decisions, and addressing
(CAPA), the Material and Product Release, the Complaint Management, the
other key matters related to pharmacovigilance; responsible for
Adverse Drug Reaction Monitoring, and the Emergency Response for Drug Safety conducting risk assessment of drug safety incidents across the Company,
Incidents. These clearly stipulate the processes and requirements for drug recalls, Decision- determining the level of emergency response, issuing directives to
emergency response to drug safety incidents, and production quality accident Making Level activate emergency response plans, and fulfilling approval responsibilities
investigations, ensuring effective control of product quality throughout its full for critical documents associated with pharmacovigilance activities in
accordance with regulatory requirements.
lifecycle.
General Manager
Applicable Product Quality Laws and Regulations As enterprise person-in-charge and the first person responsible for
quality, serves as commander-in-chief of Level 1 Emergency Command
Headquarters, responsible for emergency response of especially major or
China International major drug safety events.
Quality Head
■? Drug Administration Law of the People's Republic of China ■? EU GMP Guidelines Management
As deputy commander of the Level 1 Emergency Command Center,
Level
■? Measures for Supervision and Administration of Drug ■? PIC/S PE-009-18 Guide responsible for assisting the commander in conducting assessment,
Production to Good Manufacturing discussion, and decision-making on drug safety incidents; and as
Practice for Medicinal commander of the Level 2 Emergency Command Center, responsible for
■? Good Manufacturing Practice for Drugs (2010 Revision) approving the resolutions of the Level 2 Emergency Command Center,
Products
■? Measures for Drug Recalls and leading and directing emergency response operations for significant
■? ICH Q7 Guide to and general drug safety incidents.
■? Measures for Reporting and Monitoring of Adverse Drug
Good Manufacturing
Reactions Qualified Person
Practice for Active
■? Technical Guidance Principles for Safety Risk Pharmaceutical The Qualified Person (QP) independently assumes responsibility for the
Communication of Marketing Authorization Holders Ingredients market release of drugs, reviews the compliance of each batch and signs
■? Good Pharmacovigilance Practice (GVP) Execution off its release; participates in the quality system, self-inspection, validation,
adverse reaction handling, and product recall, and bears statutory
Level
responsibility for the quality and safety of the released drugs.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 22
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
| Drug Safety Management Strategy
Salubris always integrates quality management into the full lifecycle of drug
Salubris attaches great importance to drug safety and pharmacovigilance
R&D, production, and post-market. The Company establishes a management
work, constructing a drug safety management architecture coordinated by
system covering material management, production process control, quality
the Pharmacovigilance Person-in-Charge, with the Drug Safety Department
testing, product release review, periodic quality review, complaint handling, and
as the execution hub, and the Group Research Institute and various functional
product recalls, ensuring the safety and effectiveness of every batch of products
departments providing technical support.
through professional equipment and standardized processes. Meanwhile, the
Company continuously carries out quality training and emergency drills, promoting
Salubris Drug Safety Management Structure quality awareness deep into all staff, and actively participates in industry quality
management exchanges; multiple practices have received industry recognition.
■? Serves as head of Emergency Command Headquarters Hazard
Pharmacovigilance Control Group, coordinating and managing drug risk control | Quality Testing After product approval,
Person-in-Charge work, receiving major situation reports from the Drug Safety ongoing stability study results
Department. The Company places great importance on serve as a critical mechanism
comprehensive quality control throughout for monitoring quality and
■? Establish and improve risk prevention and control, monitoring, the entire manufacturing process. It is safety risks. This continuous
reporting, and warning systems; equipped with a wide range of precision oversight ensures that every
Drug Safety ■? Investigate clustering of adverse reactions/events and regional analytical instruments covering all batch complies with approved
required testing items for pharmaceutical specifications and internal
Department distribution;
■? Collect safety information, carry out signal monitoring and
products, including high-performance quality standards, preventing
liquid chromatography (HPLC), gas products with quality defects
benefit-risk assessment.
chromatography (GC), dissolution testing or potentially unsafe products
systems, stability chambers, atomic from reaching the market.
■? Participate in drug safety event assessment, discussion, and absorption spectrophotometers (AAS), During the reporting period,
Group Research decision-making; gas chromatography-mass spectrometry commercialized product release
Institute Clinical ■? Evaluate correlation of drug safety event data provided by (GC-MS), and liquid chromatography- pass rate and market supervision
Center various departments, judge event development trends and mass spectrometry (LC-MS). These sampling inspections pass rate
impact scope. capabilities support a well-developed are both 100%.
testing and inspection platform that enables
■? Provide supportive services such as emergency testing and full quality control from raw materials During the Reporting Period
Various Functional and intermediates to finished products,
inspection, technical identification, medical retrieval, and
Departments ensuring the safety, efficacy, and consistent
summary analysis.
quality of pharmaceuticals. In daily quality
management, the Company assigns full
responsibility to the Quality Assurance (QA) commercialized product
department for the integration and analysis release pass rate
of production, inspection, and stability
data, and conducts in-depth investigation
and assessment of deviations, Out-of-
Specification (OOS) situations, and other
quality factors, ensuring timely identification market supervision sampling
and systematic tracing of quality risks. inspections pass rate
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 23
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
| Quality Audits
Salubris establishes an annual quality audit mechanism, strictly carrying out audit
work according to the Good Manufacturing Practice for Drugs (2010 Revision) and
its appendices of China, the PIC/S GMP Guidelines, and the EU EudraLex Volume
compliance reviews across the Company's production sites. In 2025, the Company
completed multiple quality audit work, with audit scope covering non-sterile active
pharmaceutical ingredients, sterile active pharmaceutical ingredients, tablets,
sterile injectables, and other categories of production sites and related quality
management systems. Through a combination of on-site inspections and system
evaluations, we comprehensively examine the effectiveness of each factory in
quality control, risk management, and compliant operations, ensuring stable quality
and controlled safety throughout the product lifecycle.
| Product Recalls
Salubris has established the Product Recall Management Procedures, During the Reporting Period
which provide a classified recall response mechanism and define recall
triggers, investigation assessment procedures, decision-making processes,
and requirements for the handling and disposal of recalled products. Upon
identifying quality defects or potential safety risks in marketed products,
the head of quality organizes a comprehensive investigation and quality
and safety assessment, determines the appropriate recall level based on products recalls due to product recall
the severity of the potential harm, and initiates and implements the recall health and safety issues incidents
plans. Recalled products are verified, registered and quarantined by the
Material Control Department. Following analysis and assessment by the
Quality Head, the products are handled through supervised destruction,
rework, or other compliant methods to eliminate safety hazards.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 24
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
| Quality Culture
Salubris has always treated quality and
safety training as a cornerstone of its
quality culture, embedding it throughout
the product life cycle. The Company has
established a multi-level training system
that covers all operational sites and
extends across the full pharmaceutical
value chain—from R&D and manufacturing
to testing and distribution. It has also set
clear annual quality training requirements
for all employees, ensuring that everyone,
from senior management to frontline
operators, has the quality and safety
awareness and professional competence
required for their roles. During the
reporting period, participation in product
quality and safety training reached 100%.
Salubris Quality Culture Training and Awareness Campaign
Initiatives Actions
■? Conduct emergency response training at least once annually and emergency drills at least once every three years
During the reporting period
Emergency Drills to validate the receipt and handling procedures for adverse events, thereby continuously enhancing emergency
response capabilities for quality and safety incidents.
■? Organize at least 1 mock recall activity every three years; exempt if there is actual recall behavior within three years;
The proportion of employees
Mock Recalls ■? Fully examine the effectiveness of company and distributor recall systems, discuss problems and deficiencies
accepting product quality found, formulate improvement measures, and form written summaries.
training was
■? After each quality safety accident, organize cross-factory sharing to promote accident experience transmission
Cross-Organization
Experience Sharing
among operating locations;
■? Include management loopholes in annual quality system audit plans, promote system optimization through
internal audits or management reviews.
"Xin Xue Tang" ■? Carry out "Product Knowledge Learning Month" activities, focusing on core product lines in hypertension treatment,
Online Learning metabolic disorders, orthopedics, and nephrology, and systematically delivered specialized training sessions. In
Platform 2025, the activity launched over ten high-quality courses, each attracting 900+ to 2,000 employees to participate.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 25
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
| Industry Quality Awards
Salubris regularly carries out quality management group activities, quality breakthroughs, and process optimization,
continuously participating in industry quality management result exchanges. Multiple case studies have received
industry recognition and honors, providing reference examples for high-quality development of the pharmaceutical
industry.
Salubris Won Multiple Honors at the National Pharmaceutical Industry Quality
Case Management (QC) Group Achievement Presentation Exchange Meeting
In October 2025, Salubris participated in the 46th National Pharmaceutical Industry Quality Management
(QC) Group Achievement Presentation Exchange Meeting. Selected QC topics covered production
optimization, quality control, and other fields. Topics around intelligent management of reagents and
standard substances, product particle size control, and capacity improvement won First Prizes; topics
focusing on improving Chemical Oxygen Demand (COD) and Total Nitrogen treatment efficiency in
environmental station wastewater won Second Prizes; several topics secured the "Best Presentation
Awards."
Salubris Won Multiple Honors at the National Pharmaceutical Industry Quality
Management (QC) Group Achievement Presentation Exchange Meeting
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 26
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Impacts, Risks, and Opportunities Management
The Company continuously improves drug risk monitoring and early warning mechanisms. According to national drug
sampling, adverse reaction monitoring, medical institution and patient feedback, etc., we formulate and dynamically
adjust the Company's drug safety risk monitoring scheme, proposing analysis and assessment opinions on risk factors,
risk levels, impact scope, urgency, and possible harms.
Salubris Drug Safety Risk Event Control Measures
Potential Risk Factors Risk Control Measures
■? Revise drug instructions;
Risks Caused by Irrational or
■? Issue Letters to Medical Personnel and Patient Medication Safety Tips;
Erroneous Clinical Drug Use
■? Assign experts for on-site guidance on clinical medication.
■? Timely initiate risk assessment work, write assessment reports and analyze risk influencing
factors;
Determined as New Adverse
■? If risk may seriously endanger patient life safety or public health, immediately take risk
Reactions
control measures such as suspending production, sales, and recalling products, and
report to provincial drug supervision departments.
■? Under government guidance, carry out proper disposal, consolation, medical treatment,
Post-Event Recovery
compensation, insurance claims, etc., for affected personnel.
The Company implements four-level grading management for drug safety events, dividing based on dimensions such
as number of adverse events, number of serious adverse events, and number of deaths, corresponding to different
levels of emergency command systems and reporting time limits. For Level I (Especially Major) and Level II (Major)
events, we ensure telephone reporting is completed within 30 minutes, and written reports are formed within 1 hour to
properly and timely resolve drug safety events.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 27
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Metrics and Targets
The Company is committed to
safeguarding public health and life
safety, constructing a quality target
system around dimensions such as
product safety and effectiveness, recall
notification timeliness, emergency
graded response timeliness, and the
"Three No-Tolerance" principle for
accident investigations management.
We have established a comprehensive
accountability and incentive framework
that recognizes outstanding teams
and individuals for their exceptional
contributions to drug safety incident
response, while holding accountable
those responsible for delayed reporting,
concealment, or negligence or
dereliction of duty in incident handling,
thereby ensuring quality objectives are
consistently achieved.
Salubris Quality Target System
■? Set commercial product perfect batch rate targets, each factory must reach 90%, to ensure product safety and effectiveness, effectively
Product Safety and Effectiveness reducing product safety hazards.
■? With the target of achieving 100% market supervision sampling inspection pass rate, we ensure the health and safety of end?consumers.
Recall Notification Timeliness ■? Ensure Level 16 recalls notify distributors and medical institutions within 1 day, Level 27 within 3 days, Level 38 within 7 days.
Accident Reduction ■? Reduce repeated occurrences of production quality accidents, avoid development and spread of production quality accidents.
"Three No-Tolerance" principle for ■? The principle requires that the root cause be identified, relevant personnel be properly trained, and corrective and preventive actions
accident investigations (CAPA) be implemented before an investigation is considered closed.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 28
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Focusing on Technological Salubris R&D and Innovation Governance Structure
Level Main Functions
Innovation
Salubris pursues an innovation-driven development The Company establishes three governance roles: Chief Scientist, Project
strategy and has established an integrated framework Management Office (PMO), and Review Meeting Participants.
covering R&D governance, intellectual property and
■? As the academic lead for the project, the Chief Scientist has ultimate decision-
research ethics. The Company maintains a strong
making authority and provides technical guidance, ensuring that R&D priorities remain
commitment to compliance, optimizes resource allocation,
scientifically rigorous and forward-looking.
accelerates translation of research into applications, and
■? PMO is responsible for organizing and coordinating review meetings, tracking review
is committed to serving patient health with high-quality Decision-making Level progress records, and compiling review reports, ensuring process standardization and
innovation results.
transparency.
■? Review Meeting Participants are divided into Research Center Level and Group Level
reviewers based on the significance of each review stage; Group Level review scope
Governance covers Director of the Research Institute, Vice Director, Chief Medical Officer, and heads
of Market, Finance, Production, and Quality Centers, who make cross-departmental
Salubris takes innovation as the engine and deepens its comprehensive decisions on major projects.
focus on the CKM chronic disease treatment area. We
are committed to accelerating translation of frontier
research into applications through system optimization
and mechanism-driven innovation. By delivering more ■? Optimize R&D system organizational structure, independently establish Biological Drug
high-quality research outcomes to global patients, we aim Innovation Discovery Center and Chemical Drug Innovation Discovery Center, reporting
to create shared value that aligns corporate growth with directly to the General Manager to improve response speed;
social impact. ■? Simultaneously establish Small Nucleic Acid R&D Department, Biology Department,
Execution Level
Computer-Aided Drug Design (CADD) Department, and Pipeline Strategic Planning
Department, forming an R&D matrix covering chemical drugs, biological drugs, small
| R&D and Innovation Governance nucleic acids, peptides, and cyclic peptides, strengthening synergy efficiency of source
Architecture innovation and strategic management.
Salubris strictly follows internal systems such as the R&D
Project Review Management Measures and the R&D
Project Incentive Management Measures, formulating the ■? Implement large project system management; Each project sets a Project Leader
R&D System Five-Year (2026-2030) Development Plan to responsible for overall promotion, strengthening process control and cross-
provide programmatic guidance for company R&D work. departmental collaboration;
Project Operation Level
The Company establishes a layered R&D and innovation ■? Simultaneously enhance management execution and frontline engagement, requiring
governance architecture, clarifying functions at all levels managers to go deep into frontlines to solve technical, process, and management
to ensure the R&D system operates in a standardized and problems, ensuring effective transmission of governance system at the execution end.
efficient manner.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 29
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Strategy | Leading Industry Development
Salubris has established a multi-dimensional R&D incentive mechanism, actively
laid out cutting-edge technologies, and continuously enhanced its independent Capitalizing on the strategic opportunity for China's pharmaceutical industry to
innovation capabilities, contributing positively to the high-quality development of transition from "Me-too" to "Best-in-Class" and "First-in-Class”, Salubris continues
the industry. to increase innovation investment. From 2021 to 2025, cumulative R&D investment
reached RMB 4.9 billion, injecting strong momentum into the rapid expansion of the
product pipeline.
| R&D Incentive Mechanism The Company has cultivated a significant first-mover advantage in the CKM
chronic disease treatment field centered on cardiovascular and cerebrovascular
Salubris has established the R&D Project Incentive Management Measures, diseases. Specifically, in the hypertension sector, the Company has successfully
adhering to the core principles of "taking strivers as the foundation, centering on launched four new drugs. We persist in technology leadership, proactively
patient needs, and orienting towards project outcomes." This framework builds an deploying an AI-enabled innovative drug development system. By continuously
R&D ecosystem in which employees and the company achieve win-win value. We optimizing CADD (Computer-Aided Drug Design) and AIDD (AI-Driven Drug
have developed five categories of R&D project rewards, forming an incentive matrix Discovery) platforms, we are dedicated to creating proprietary AI chemical
that covers the entire lifecycle from project initiation and development to technical innovative drug design algorithms to drive a leap in R&D efficiency through
breakthroughs and special contributions. Reward standards comprehensively technological empowerment.
consider multiple dimensions such as expected returns, development models,
registration classifications, difficulty coefficients, and project progress. Additionally,
we have established a key milestone review mechanism spanning the entire
product lifecycle, from lead molecule discovery to obtaining production approval.
This includes pharmaceutical research, preclinical pharmacology and toxicology
trials, clinical bioequivalence (BE) trials, and Phase I to III clinical studies. Upon
successful review at each milestone, teams become eligible to apply for
corresponding bonuses, ensuring incentives precisely target the R&D frontline.
| R&D Innovation Projects
From 2021 to 2025,
Salubris is deeply engaged in R&D and innovation, focusing on the cardiovascular-
kidney-metabolic (CKM) field while addressing domestic market demands
and clinical pain points, with forward-looking deployment for potential external
licensing. Regarding its self-developed innovative drug pipeline, the Company
has constructed a complete product pipeline ranging from early discovery to
market registration. Between 2021 and 2025, we cumulatively obtained multiple
novel lead compounds and identified several Preclinical Candidate Compounds
RMB 4.9 billion
(PCCs) through screening, completed numerous Investigational New Drug (IND) cumulative R&D
applications, and advanced several varieties to Phase III clinical trials, New Drug investment reached
Application (NDA) stages, or market approval. We are actively building small
nucleic acid and peptide/cyclic peptide innovation platforms, which are now
entering a concentrated period of early discovery transformation and have
successively obtained multiple new PCCs.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 30
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Impact, Risks and
Opportunities Management
Salubris strictly adheres to relevant
laws and regulations on experimental
ethics, as well as the requirements
of the World Medical Association's
Declaration of Helsinki (Revised
October 2024). We have formulated
and implemented the Charter for
the Work of the Experimental Animal
Management Committee and Ethics
Committee and the Ethics Submission
Management Procedure, covering
animal experiments and human
clinical trial ethics in their entirety to
ensure full compliance throughout the
R&D process.
| Animal Experiment Ethics
The Company has established two independently We implement a pre-approval mechanism endpoints; experiments are terminated
operating specialized institutions: the Experimental where projects cannot proceed without immediately upon triggering these
Animal Management Committee and the approval ("review first, then conduct; no standards to prevent unnecessary
Experimental Animal Ethics Committee, responsible review, no implementation"), upholding suffering. During the reporting period,
for management supervision and ethical review, the 3R principles (Replacement, Reduction, no violations of animal experiment
respectively. The Management Committee Refinement) for animal use. Standardized ethics occurred.
oversees facility operations, daily supervision, forms ensure all review processes are
and penalties for violations; the Ethics Committee documented and archived. We provide
focuses on project review, ongoing supervision, and training on animal experiment operations, During the reporting period
animal welfare assurance. Committee members including acclimatization feeding,
include veterinarians, researchers, and quality administration, and blood sampling,
management personnel, serving three-year terms
with regular rotations. The committees convene at
to minimize harm to animals. In pain
management, we monitor anesthetic
No violations of animal
experiment ethics occurred.
least once annually to evaluate its operations. responses in animals and set clear humane
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 31
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
| Human Clinical Trial Ethics
To ensure the standardized conduct of drug clinical trials and the scientific validity, accuracy, and reliability of data and
results, while safeguarding the rights and safety of trial participants, we will strictly adhere to the approved protocol and
applicable Chinese laws and regulations. All trial activities will be conducted in compliance with the World Medical Association's
During the reporting period
Declaration of Helsinki (Revised October 2024), ICH E6 (R3) GCP, and the Good Clinical Practice for Drug Trials (2020 Edition),
with all relevant responsibilities duly fulfilled.
The rights, safety, and well-being of trial participants are the paramount considerations and shall take precedence over
scientific and societal benefits. Ethical review and informed consent serve as fundamental safeguards for protecting
participants' rights and safety. We strictly uphold core ethical principles—including informed consent, privacy protection, and
risk control—to ensure full compliance with national regulations and internationally accepted standards throughout the trial.
No clinical trial shall commence without prior approval from the Ethics Committee (EC). Throughout the study, the trial will
No violations of human
clinical trial ethics occurred.
be conducted in strict accordance with the approved protocol. Any amendment to the protocol must be implemented only
after it has been communicated to and agreed upon by the sponsor, and subsequently re-approved or filed with the Ethics
Committee, unless such measures are necessary to protect the safety, rights, and welfare of trial participants.
Salubris Human Clinical Trial Ethics Management System
■? The Clinical Research Project Manager (CPM) coordinates document preparation and review to ensure consistency of submission versions
Initiation Phase across centers.
■? Clinical Research Associates (CRAs) precisely align with center review requirements, tracking progress until written approval is obtained.
■? Strictly fulfill dynamic supervision duties, timely update documents involving trial participants safety, report safety information such as
Execution Phase serious adverse events (SAEs), protocol deviations, and pregnancy data within prescribed timeframes, and regularly submit the Clinical
Research Periodic Progress Reports.
Conclusion Phase ■? Properly archive ethics close-out documentation, ensuring all documents are completely saved for full-process traceability.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 32
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
| Intellectual Property Management
Salubris complies with laws such as the Patent Law of the People's Republic of China and strictly follows
internal systems including the Patent Management System, the Trademark Management System, the
Confidentiality System, and the R&D Project Review Management Measures to ensure effective protection
and application of intellectual property rights. The person primarily responsible for intellectual property
is included in the list of participants in research center-level review meetings, ensuring an independent
voice for IP perspectives in project initiation and key decisions at critical project stages, thereby avoiding
infringement risks at the source and expanding technical value.
In terms of protection strategy, the Company systematically advances efforts across three dimensions:
Salubris Intellectual Property Protection Measures
Strategic Dimension Core Measures
■? For listed innovative drugs, collaborate with business departments to deeply explore
IP Protection for
technical details, continuously extend peripheral patent layouts, and strengthen the
Innovative Drug Products
patent defense system for innovative products.
■? Plan overseas application paths for core patents in advance based on external
licensing needs.
Overseas Rights Layout ■? Collaborate with overseas patent attorney teams that bring a global perspective to
provide customized IP support for outbound products, safeguarding legal rights in
global markets.
■? Closely track changes in industry policies and regulations and adjustments in patent
Dynamic Maintenance examination standards across countries, establishing a flexible patent portfolio
and Optimization management mechanism to timely optimize patent layout and maintenance
strategies.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 33
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Salubris Participated in the "Law Interpretation Through Ten Cases" – Interpretation of Typical
Case Patent Reexamination and Invalidity Cases in 2025
Salubris organized employees related to intellectual property management to participate in the "Law Interpretation
Through Ten Cases" event hosted by the Patent Reexamination and Invalidation Department of the China National
Intellectual Property Administration. The event selected ten high-profile, influential, and guiding typical cases
from 2025 to deeply interpret patent examination standards and clarify patent protection rules. Through this
learning activity, Salubris continuously strengthened the professional capabilities of its IP management team,
improved compliance levels in patent portfolio, risk prevention, and rights maintenance, and provided more solid
IP protection support for innovative drug R&D achievements.
During the reporting period
patent applications filed
Participate in the working Exchange for the Demonstration Internal Study on Patent Invalidation Cases
and Creation of Intellectual Property Powerhouse
Construction
In 2025, Salubris achieved significant results in intellectual property work. The Company filed 241 patent applications, including
the reporting period, we had cumulatively obtained 392 valid patent grants, providing a solid legal and technical barrier for
continuous innovation.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 34
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Metrics and Targets
Salubris maintains high-intensity The Company has constructed a technological innovation target system covering
technological investment, allocating four dimensions, breaking down strategic goals into annual execution plans for
resources in both funding and 2026–2030 to form a trackable and assessable target management mechanism.
manpower.
Salubris Technological Innovation
Salubris Technological Innovation Targets
Investment Indicators
During the reporting period
Obtain approval of multiple new products or
Growth Goals
new indications;
RMB 1.266 billion
R&D investment amount
Internationalization Promote multiple products for overseas
% Goals licensing or overseas sales;
R&D investment as a percentage
of annual revenue
Goals
Maintain CKM chronic disease clinical R&D
pipeline among the top tier domestically;
number of R&D personnel
percentage of R&D personnel Organizational Strengthen organizational mechanisms and talent
Development Goals teams aligned with innovative R&D
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 35
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Putting Patients First Salubris Customer Service Governance System
Salubris has consistently upheld its business philosophy Company’s ■? Exercises ultimate authority regarding significant product quality complaints and the handling
of "Goodness begins with integrity" and adhered to the Head of Quality or recall of marketed products.
core value of "putting patients first." We regard customer
■? Serves as the unified external contact window, responsible for full-chain management from
trust as the cornerstone of the Company’s long-term and
receipt, transfer, process communication to result feedback and negotiation, ensuring timely
sustainable development. Grounded in the characteristics
and transparent complaint handling;
of the pharmaceutical industry, we serve five key groups:
■? Establishes and maintains complaint ledgers, regularly analyzes complaint trends for each
healthcare institutions and medical professionals,
Quality Center variety, and feeds back prominent quality issues to the production side to drive rectification
commercial and channel partners, retail outlets, patients
measures;
and their families, and overseas customers and partners.
■? Responsible for standardized organization, archiving, and maintenance of all complaint
We are committed to building a service ecosystem that
handling records and related document files, ensuring compliance and traceability of the
covers the entire product lifecycle.
quality management process.
■? Sales Department: Acts as the front-end information hub, responsible for collecting and initially
Optimize Service verifying customer complaint details, assisting in communicating handling solutions with
customers when necessary, and cooperating with investigations;
■? Production Department: Responsible for investigating root causes of complaints, drafting
Business
| Customer Service Governance System investigation reports, formulating and implementing corrective and preventive measures, and
Departments
providing technical support on product usage;
Salubris has built a customer service governance and Functional
■? Quality Control Department: Responsible for conducting retention sample or sample testing,
system led by the Company's Head of quality, centered Departments
issuing analysis reports to assist in investigating causes of out-of-specification or abnormal
on the Quality Center's customer service department,
situations using scientific data;
and coordinated by multiple departments, forming
■? Other Functional Departments: Provide professional support in medical and technical fields for
an organizational guarantee mechanism with clear
complaint handling to ensure accurate and reliable technical judgment for complex problems.
responsibilities and rapid response.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 36
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
clock on working days and immediate safety information is reported within
| Customer Service
archiving of voice messages during 24 hours, effectively resolving potential
Guarantee Mechanism | Customer Satisfaction
non-working hours with dedicated risks. After receiving complaint
follow-up. Meanwhile, we continuously information, customer service The Company conducts satisfaction
The Company continues to improve enhance the professional capabilities specialists complete initial registration surveys with consulting customers
its customer communication of the customer service team, and validity judgment based on the every half year, transforming
management system, formulating and requiring staff to strictly follow "Complaint Handling Coordination customer feedback into motivation
strictly implementing internal systems internal regulations such as the Drug Table" and convey valid complaints to for improving product quality and
such as the Product Complaint Adverse Reaction Reporting and the factory's Quality Assurance (QA) driving simultaneous upgrades
Handling Management Procedures Monitoring Management System and department within 48 hours to initiate in service quality and customer
and the Incoming Call Answering investigation. During the investigation
master product knowledge, ensuring experience.
and Message Management. We phase, progress is synchronized
professionalism and reliability in every
integrate diverse channels, set up periodically; if necessary, on-site visits
interaction.
dedicated customer service hotlines, are arranged. Investigation results During the reporting period
comprehensively covering quality are reviewed by the QA manager and
complaints, medication consultations, the person responsible for quality at
| Customer Complaint
and adverse reaction reports, the plant before being uniformly fed
extending feedback to terminal Handling
back to the customer by the customer
networks including distributors, service specialist. During the reporting
hospitals, and pharmacies, ensuring The Company has established a period, the Company accepted a complaint events occurring
all complaints are included in a management process from complaint total of 67 customer complaints, with
unified tracking and handling process. registration, internal collaborative no major complaint events occurring.
We strictly enforce standardized investigation to rectification feedback.
All complaints achieved a 100%
answering norms and message For quality-related complaints, processing rate.
management processes, ensuring cross-departmental root cause
professional response around the investigations are initiated to ensure complaint processing rate
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 37
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Responsible Marketing
Salubris integrates the concept of responsible marketing into every link of commercial activities. By creating a fair competition
market environment, standardizing academic promotion behaviors, and strictly observing professional ethics, the Company is
committed to building a transparent, healthy, and sustainable pharmaceutical marketing ecosystem, guarding public health.
monopoly agreements and abusing non-compliance incidents involving eliminating any improper behavior. For
| Responsible Marketing
market dominance. For high-risk product information, labeling, or discovered problems, we adhere to a
Management scenarios involving communication marketing communications related to "zero-tolerance" principle, immediately
of competitively sensitive information, false marketing. initiating rectification procedures
Salubris always abides by the joint sales and procurement, industry and implementing accountability
principles of fair competition and standard setting, and bidding, strict mechanisms, continuously promoting
honest operation, ensuring all pre-approval mechanisms must be | Responsible Marketing the standardization and transparency
marketing means comply with local followed, requiring approval from Audit construction of the marketing system.
laws and regulations such as the Anti- legal and risk control departments. It
Monopoly Law of the People's Republic is strictly prohibited to use algorithms, The Company has established a
of China. The concept of responsible data advantages, or platform rules systematic responsible marketing
marketing is clearly defined in to exclude or restrict competition. audit mechanism, conducting
| Responsible Marketing
the Anti-Monopoly Management Compliance responsibilities are
System and integrated into the
internal audits and special audits Training
incorporated into the performance annually to comprehensively review
entire process of drug information assessment of marketing post The Company continues to optimize
the compliance, authenticity,
dissemination and professional employees, urging them to the compliance and responsible
and transparency of marketing
academic exchanges, conveying consciously regulate professional marketing training system, adopting
activities. Audit scope covers key
product information in a scientific, behavior and observe the bottom diverse modes such as offline lectures,
links such as promotional materials,
accurate, and transparent manner line of professional ethics, jointly online studies, mentorship guidance,
expense reimbursement, meeting
to safeguard medical decision- creating a clean, healthy, and orderly and thematic seminars to enhance
management, and interactions with
making and patient life safety. The marketing ecosystem. In 2025, the the depth of interaction and practical
stakeholders, ensuring all marketing
Company prohibits implementing Company did not experience any effectiveness of training.
activities focus on patient interests and
During the reporting period
or marketing communications related to false marketing.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 38
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
Industrial Synergy Salubris Supplier Management Process
and Common The Company strictly complies with internal documents such as the Raw Material and Packaging Supplier Entry
Prosperity Entry
Standards, setting differentiated "mandatory" and "reference" items for manufacturers and traders for entry evaluation,
verified through Tianyancha checks, on-site inspections, third-party surveys, etc. Evaluation items include quality
Salubris deepens full-lifecycle supplier standards, price, scale of personnel, Health, Safety and Environment (HSE) management risks, and credit status.
management, committed to building
a robust and efficient supply chain
system. The Company strengthens
ESG risk identification and control The Company builds a regular, quantifiable supplier performance evaluation system, achieving full-cycle performance
capabilities, achieving common control through a combination of annual comprehensive assessments and quarterly special dynamic evaluations.
Evaluation
prosperity and shared responsibility Evaluation results are linked to cooperation opportunity allocation, share adjustment, deepened collaboration, and exit
through synergy, joining hands elimination.
with supplier partners to create a
sustainable ecosystem of shared
value.
At the beginning of each year, the Company formulates a supplier grading plan for the year according to the
Annual Procurement Plan & Strategy, dividing suppliers into core suppliers, key suppliers, general suppliers, and low-
Supplier Management performance suppliers, taking differentiated management measures.
Salubris strictly complies with the laws ■? Core Suppliers: Deeply synergistic in technology, capital, or strategy and crucial to business; deep cooperation is
and regulations in the jurisdictions Tiered ensured through high-level mutual visits and early project intervention.
where it operates. The Company Management
■? Key Suppliers: Preferred suppliers with large procurement amounts, high dependency, or excellent performance;
has established internal policies and close interaction is maintained through long-term agreements and technical cooperation.
procedures, including the Procurement ■? General Suppliers: Qualified or not subject to performance assessment; divided into A, B, and C categories based on
Management Policy and the Supplier performance. Resources are appropriately tilted towards Class A suppliers on the basis of fair competition.
Management Measures, to develop a ■? Low-Performance Suppliers: Those with safety/quality accidents or substandard performance; business restrictions,
comprehensive supplier management backup finding, and gradual elimination measures are taken.
process that covers onboarding,
evaluation, tiered management,
and exit, thereby directing resources
toward high-performing, compliant,
and quality suppliers.
The Company resolutely implements a supplier rectification and exit mechanism. For suppliers with minor compliance
flaws or management irregularities, time-limited rectification is required; for those with delayed rectification, weak
Exit willingness, or recurring problems, introduction or cooperation is suspended; for those with major safety hazards,
environmental violations, serious quality issues, commercial fraud, illegal operations, refusal to rectify, or failed
rectification, they are blacklisted, and existing cooperation is terminated.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 39
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
The Company treats small and medium-sized enterprises equally, adhering to Supply Chain ESG Management
principles of fairness, transparency, and good faith performance of obligations,
establishing standardized, unified, and strict supplier payment and payment terms Salubris has integrated ESG concepts and compliance requirements into the
management systems. All payments are strictly executed according to formal entire supply chain lifecycle. We implement end-to-end oversight from supplier
contracts, with account periods preset in the system. Regardless of supplier size, qualification and contracting to exit. This process covers all new suppliers, requiring
cooperation cycle, or regional differences, we treat everyone equally, avoiding them to fulfill their committed responsibilities in accordance with the suppliers'
unjustified delays or malicious withholding of accounts, effectively protecting the social responsibility and code of conduct. Meanwhile, we carry out online and
legitimate rights and interests of small and medium-sized suppliers and various offline ESG exchange activities, achieving full coverage of key suppliers, actively
cooperative parties. In 2025, the Company had no overdue payments to small and promoting sustainable development concepts, urging partners to integrate
medium-sized enterprises. excellent ESG practices throughout production and operation processes, jointly
pushing the overall supply chain towards green and sustainable upgrades.
As of the end of the reporting period, the Company had a total of 2,594 suppliers.
Supplier management data is as follows:
Salubris Supplier Management Data Salubris Supplier ESG Management Mechanism
Indicator Unit 2025
■? Require suppliers to strictly comply with national and local
Environmental environmental laws and regulations, take effective measures to
Mainland China / 2,584
Number of Dimension reduce environmental impact, and promote green production and
Suppliers by sustainable development.
Region Hong Kong, Macao, Taiwan and
/ 10
Overseas
■? Prohibit suppliers from employing child labor and using forced
Number of Key Suppliers / 308 labor, requiring them to guarantee wages and benefits for all
employee groups;
■? Require suppliers to provide safe and hygienic working
Social
Suppliers Certified by ISO 14001 System / 186 environments, strengthen employee health and safety training, and
Dimension
prevent occupational diseases and work injuries;
■? Require suppliers to respect employees' rights to freedom of
Suppliers Certified by ISO 45001 System / 169 association and collective bargaining, eliminating any form of
Supplier discrimination.
Certification
Suppliers Certified by ISO 9001 System / 293
■? Prohibit any form of corruption and bribery;
Suppliers Certified by Other ■? Conduct business in a commercially ethical manner, ensuring fair
/ 130 Governance
Certifications competition;
Dimension
■? Protect all confidential information or materials provided by the
Suppliers Using Eco-friendly Materials and Circular Company and its business partners.
/ 21
Packaging
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 40
Keeping Quality Commitments Focusing on Technological Innovation Putting Patients First Industrial Synergy and Common Prosperity
The Company has built a regular risk management system covering compliance, quality, delivery, environmental safety, supply disruption, and ESG dimensions. A
procurement risk management group is established, defining "zero supply disruption, zero violation" management goals, implementing full-cycle control of pre-event
prevention, mid-event control, and post-event review. In terms of evaluation mechanisms, we adopt a mode combining daily-triggered, periodic, and special assessments,
where production materials execute quarterly routine evaluations to ensure timeliness and comprehensiveness of risk identification. During the reporting period, after
rigorous assessment, no suppliers with negative factors related to labor, environment, etc., were found, effectively safeguarding supply chain safety and stable operation.
Salubris Supply Chain Risk Management Process
Risk Identification Risk Analysis Risk Grading Risk Disposal Risk Review
The procurement risk The procurement risk Risks are classified into three ■? High Risk: Real-time tracking and Review the situation of risk
management group sorts management group analyzes levels, dynamically adjusted reporting to senior management. occurrence, effectiveness
out potential risks in each link the causes, probability, scope of according to conditions and Special disposal plans are of disposal measures, and
and category of procurement, impact, and losses of risks. state changes: formulated, submitted for approval existing problems, providing
submitting a risk identification list. according to amount and nature dynamic control measures
■? High Risk: High probability of
levels, and key difficult matters are and optimization suggestions,
occurrence, severe impact;
recorded throughout the process. compiling annual risk event
■? Medium Risk: Relatively high
■? Medium Risk: Monthly or weekly reports.
probability, significant impact;
reporting to responsible
■? Low Risk: Low probability,
departments; relevant departments
limited impact.
jointly dispose and track progress
and results throughout.
■? Low Risk: Quarterly communication
within business departments,
included in daily management.
The Company is committed to comprehensively enhancing supply chain resilience, establishing a full-process quality traceability system. By implementing routine sampling
inspections, conducting regular on-site audits, and ensuring timely corrective actions, the Company effectively mitigates quality risks and maintains consistent quality of
supplied products. Meanwhile, we implement diversified procurement, resource backup, domestic substitution, and safety inventory strategies to resolve single-dependency
and capacity bottlenecks at the source, building multi-level buffering mechanisms to ensure safe and sustainable supply chain operation.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 41
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Cultivating Talent, Harnessing
Collective Wisdom
Salubris adheres to a people-oriented
development philosophy, regarding
employees as the core driving force
of sustainable development. Through
continuously improving the employee
management system, the Company has
built a safe, equal, diverse, and inclusive
work environment. Focusing on employee
protection, occupational health and
safety, and talent development systems,
the Company constantly strengthens
its institutional foundation, optimizes
management practices, promotes
shared growth between employees and
the enterprise, and provides solid talent
support for high-quality development.
No 100% 59
violations training coverage average training Welfare support is provided, including paid
such as forced rate hours per annual leave, health checkups, and nursing
labor or child labor employee rooms. Online and offline communication
occurred during channels are kept open, and annual
the year satisfaction surveys for all employees are
conducted.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 42
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Compliant and Equal fairness, impartiality, and transparency. Promoting Equality and Diversity
This ensures that the entire employee
Employment hiring process strictly meets legal and Salubris embeds respect for human
Implementing To maintain an equal employment regulatory requirements, achieving rights and corporate responsibility into
standardized and transparent daily operations and strictly abides by
Compliant environment, Salubris strictly prohibits
all forms of illegal employment and operations. laws and regulations. The Company
maintains a "zero tolerance" stance
Employment complies with national laws and
regulations such as the Labor Law of
Salubris has formulated the towards all forms of discrimination and
Management Measures for Prohibiting harassment, establishing a comprehensive
the People's Republic of China and Child Labor and Forced Labor, resolutely
Salubris abides by laws, complaint reporting and investigation
the Labor Contract Law of the People's prohibiting any form of child labor and
regulations, and compliance mechanism to strive for a fair, safe,
Republic of China. The Company has forced labor. At the same time, the
guidelines, fully implements respectful, and healthy work environment.
equal employment policies, and formulated and implemented the Company has established reporting We adhere to the principle of equality
deeply embodies the concepts Recruitment Management System, channels to strengthen supervision. and do not treat employees differently
of diversity, equality, and serving as the standard and guidance Regarding cases involving child labor based on factors such as place of birth,
inclusion. The Company strives for recruitment work. Within the and forced labor, upon verification, race, socioeconomic status, nationality,
to maintain a positive, healthy, recruitment management system, we employment is terminated immediately, hometown, religion, age, disability,
standardized, orderly, and establish diverse recruitment channels victims are provided with assistance, gender, marital status, pregnancy, sexual
vibrant workplace ecosystem, and incorporate non-discrimination and responsible individuals will face orientation, or union affiliation. Meanwhile,
creating harmonious and stable as a recruitment requirement, building demotion, dismissal, fines, or legal the Company strictly implements national
labor relations. a scientifically grounded selection accountability based on the severity of regulations on working hours, overtime
mechanism, establishing standardized the circumstances. During the reporting and leave to protect employees’ rights
execution standards, and always period, no violations such as forced labor and build regulated, harmonious and
adhering to the core principles of or child labor occurred at Salubris. sustainable employment relations.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 43
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Indicator Unit 2025
Total Employees persons 4,087
Male persons 2,114
By Gender
Female persons 1,973
By Age Group 30-50 years old (inclusive of 50, exclusive of 30) persons 2,751
Over 50 years old (exclusive of 50) persons 165
Doctoral Degree or Above persons 68
Master's Degree persons 427
By Education Level
Bachelor's Degree persons 1,861
Associate Degree and Below persons 1,731
General Employees persons 3,632
By Job Level Middle Management persons 439
Senior Management persons 16
Mainland China persons 4,055
By Region
Hong Kong, Macao, Taiwan and Overseas persons 32
Han Chinese persons 3,834
By Race/Ethnicity Ethnic Minorities persons 215
Overseas Employees persons 38
Production persons 1,154
Technical persons 827
By Profession
Sales persons 1,698
General Administration persons 408
Full-time Employees persons 3,940
By Employment Type
Non Full-time Employees persons 147
Females in Grassroots Management persons 117
Females in Middle Management persons 115
Employee Diversity Females in Senior Management persons 5
Females in STEM-related Positions persons 698
Females in Revenue-generating Management Positions persons 138
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 44
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Indicator Unit 2025
Total New Hires persons 1,053
Male persons 501
Female persons 552
New Recruitment
Over 50 years old (exclusive of 50) persons 6
Indicator Unit 2025
Turnover Rate % 16
Male % 17
Turnover Rate By Gender
Female % 15
Turnover Rate By Age 30-50 years old (including 50, excluding 30) % 13
Above 50 years old (excluding 50) % 13
Mainland China % 16
Turnover Rate By Region
Hong Kong, Macao, Taiwan and Overseas % 0
General Employees % 16
Turnover Rate By Job Level Middle Management % 13
Senior Management % 0
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 45
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Empowering Employee Growth During the reporting period
To develop a high-quality talent development ecosystem, the Company has
established a systematic talent cultivation system and unobstructed career The Company achieved a
development pathways. This creates a tiered workforce that supports organizational training coverage rate of
strategy, not only providing high-quality talent supply for business growth but
also comprehensively empowering employees' capability leaps and career
advancements. 100%
Systematic Training System training. Based on organizational and employee training needs surveys, the Company formulates annual training plans
Salubris consistently places talent for each level and establishes a training mechanism combining "Internal Training for Foundation" and "External Training
cultivation at the core of its corporate for Innovation."
development strategy. To standardize Furthermore, the Company adopts a blended training model integrating online and offline approaches, building the
the training management process, the "Xin Academy" online platform that covers all enterprise learning scenarios and supports convenient learning. Platform
Company has formulated and refined courses cover multiple directions, including management leadership, various professional skills, and general literacy.
the Company Training Management Currently, the platform hosts over 5,000 courses, with employees averaging 14.5 annual online learning hours. Leveraging
System, constructing a scientific and the learning platform, the Company continues to conduct various thematic activities, such as leadership and AI
systematic training framework that initiatives, forming an integrated "Learn-Explore-Practice" model. During the reporting period, the Company achieved a
clarifies requirements and standards for training coverage rate of 100%.
various types of training. Simultaneously,
through regular assessment of training
outcomes, the Company continuously
optimizes the talent cultivation
mechanism to ensure the sustained
enhancement of training value.
The Company has built a talent
cultivation system centered on
career development pathways.
By implementing hierarchical and
categorized management, this system
covers three levels of standards: the
Company, subsidiaries/branches,
and departments. Training content
encompasses multiple categories,
including general competency training,
specialized training, and onboarding Xin Academy Thematic Training
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 46
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Indicator Unit 2025
Percentage of Employees Trained % 100
Male persons 2,114
Number of Employees Trained by Gender
Female persons 1,973
Male % 100
Percentage of Employees Trained by Gender
Female % 100
General Employees persons 3,632
Number of Employees Trained by Job Level Middle Management persons 439
Senior Management persons 16
General Employees % 100
Percentage of Employees Trained by Job
Middle Management % 100
Level
Senior Management % 100
Total Annual Training Hours hours 240,296
Average Training Hours per Employee hours 59
Male hours 62
Average Training Hours by Gender
Female hours 56
General Employees hours 59
Average Training Hours by Job Level Middle Management hours 57
Senior Management hours 18
Number of Employees Under Performance Appraisal or Career Development Assessment9 persons 3,651
Percentage of Employees Under Performance Appraisal or Career Development Assessment9 % 90
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 47
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Unobstructed Career Development Pathways Employee Career Development Pathways
Based on its actual operational conditions and employees' career development
plans, Salubris has formulated the Employee Career Development Management Leadership Training
Measures and the Job System Management Measures. Accordingly, the Company The Company has launched tiered programs such as the "Xin Class" "Li
establishes different job levels, grades, ranks, and job sequences. For R&D, Class " and "Tai Class" leadership tracks to precisely enhance management
Production, and other sequences, qualification standards are set according to capabilities for employees at different levels.
job grades, while the Management sequence sets management competency
standards according to job layers. This clarifies employee capability and behavioral
Professional Competency Training
requirements to help employees clarify goals and promote career development.
The Company adopts differentiated empowerment strategies, customizing
Salubris builds a systematic talent development system, taking the dual channels
exclusive professional growth paths for employees. Through the "Three-Level"
of "Management" and "Professional" as the horizontal core, and vertically
training system, this initiative enables senior talent to rapidly transition into
establishing promotion pathways from low to high job levels, grades, and
professional roles.
rank. Relying on the online platform "Xin Academy" and offline training projects,
comprehensive support is provided. Employees can flexibly choose promotion
New Talent Training
within the same channel, cross-channel development, or lateral transfers to
broaden their professional scope, enhance comprehensive capabilities and The Company has established a three-year structured development
person-job fit, thereby optimizing performance. program for campus recruitment management trainees to build their
professional capabilities and support their long-term career development.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 48
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Unlocking Employee Potential organizational efficiency and employee personal development levels.
The Company continuously improves the medium-to-long-term incentive
The Company continuously improves the closed-loop performance management system and orderly implements employee equity incentive arrangements, deeply
mechanism, aligning individual performance and contributions with the Company’s linking them with annual performance results to improve the precision of the
long-term strategic objectives. It establishes a long-term link between core talent incentive mechanism and strengthen the synergy matching between incentive
incentives and the Company's long-term development, strengthening the internal orientation and strategic goals. Through building a diversified reward system and
drive for sustainable organizational development. Meanwhile, the Company is unobstructed career development pathways, the Company consolidates talent
committed to building an inclusive and open workplace ecosystem, streamlining introduction, cultivation, incentive, and retention capabilities, strengthens core team
channels for employees to express concerns, improving feedback response cohesion, and provides talent support for the enterprise's sustainable operation
mechanisms, and effectively safeguarding employees' legitimate rights and and development.
interests.
Diversified Incentives Employee Care
Salubris strictly complies with laws and regulations such as the Social Insurance Salubris strictly complies with national and local labor laws and regulations,
Law of the People's Republic of China, the Company Law of the People's Republic formulates the Attendance and Leave Management Measures, and continuously
of China and the Securities Law of the People's Republic of China, and formulates improves non-compensation welfare guarantee mechanisms. The Company
internal regulations such as the Compensation Management Measures and the systematically builds an employee care system covering health care, welfare
Performance Management Measures. The Company is committed to building a support, and work-life balance, focusing on creating a reassuring, warm workplace
fair, transparent, and market-competitive compensation and benefits system. By environment with a strong sense of belonging.
continuously advancing the standardization and normalization of its compensation
system, the Company has established a salary structure centered on fixed salary,
performance bonuses, and supplementary allowances. It has also introduced
supplementary benefit programs covering holiday allowances, commercial 2025 Salubris Employee Benefits
insurance, and other items to effectively safeguard employees’ rights and
interests. The Company binds employees' individual performance and job value Provide employees with various personal leave including paid annual leave, welfare
to the Company's long-term development, ensuring incentive effectiveness while leave, paid sick leave, maternity leave, paternity leave, and nursing leave, along with
considering the guarantee function, thereby stimulating organizational vitality health checkups, supporting employees in reasonably balancing work and life;
comprehensively.
Regularly host diverse cultural, sports, and festival-themed activities, and provide
The Company has established and implemented a performance management holiday greetings, birthday perks, and customized uniforms at key occasions to
system covering all employees and departments, standardizing the management foster team cohesion.
of individual and departmental performance goal commitment forms and their
decomposition processes to ensure the clarity and traceability of goal setting. Provide localized amenities such as talent apartments, staff dormitories, employee
The Company initiates team and individual performance assessment work, cafeterias, recreational facilities, and commuter shuttles to significantly enhance
formulating performance goal commitment forms and process flowcharts to daily convenience and off-work quality of life.
ensure the orderly implementation of assessment work. In addition, the Company Offer annual health screenings and an employee mutual aid program (covering
attaches great importance to the performance feedback and improvement links, hospitalization, critical illness, and accidents), alongside dedicated support and
regularly conducting performance interviews and formulating detailed feedback condolence initiatives for critical illness, maternity, or the loss of an immediate family
and improvement plans. This forms a management closed loop of "Goal Setting member.
– Assessment Execution – Feedback Improvement" to continuously improve
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 49
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Employee Communication and Satisfaction
Salubris respects individual differences and diverse backgrounds of employees, assisting corporate culture construction and business strategy implementation,
and is committed to creating an equal and inclusive internal communication and strengthening team cohesion. The Company has now formally included the
atmosphere. It establishes multi-level, institutionalized employee communication performance appeal process in the performance management system, supporting
and democratic participation mechanisms, fully safeguarding employees' rights and perfecting standardized forms for performance appeals and performance
to know, participate, and express. This guides employees to deeply participate in interviews, further completing the closed loop of employee communication
enterprise construction, ensuring every employee's voice is heard and demands feedback and rights protection.
are handled fairly and timely.
To clarify organizational development direction, Salubris conducts annual
The Company builds a three-dimensional communication channel combining satisfaction surveys for all employees, covering dimensions such as welfare
online and offline links, supplementing real-name and anonymous methods. policies, compensation performance, occupational health, etc., to comprehensively
Through OA systems, collaborative forms, suggestion boxes, dedicated feedback gain insights into core advantages of organizational management and key areas
emails, and other channels, employees are supported to conveniently and urgently needing improvement in the future. Based on survey results, the Company
efficiently express views and feedback demands regarding process optimization, quickly implements optimization measures and plans annual improvement
training experience, system iteration, daily management, etc. The Company strategies, effectively absorbing employee feedback, continuously improving the
continuously listens to employees' voices and responds to reasonable suggestions working environment, and creating an excellent organizational atmosphere.
in time, promoting collaboration among employees from different backgrounds,
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 50
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Ensuring Health and Safety
Salubris adheres to the occupational health and safety policy of "people-oriented, ensuring safety production" regarding the health and safety of employees and
stakeholders as the cornerstone of the company's sustainable and robust development. Guided by the occupational health and safety objectives of "zero work-related
fatalities and injuries and zero occupational disease cases," we deeply integrate occupational health and safety management into the full process of R&D, production, and
operations, continuously fostering an inherently safe, healthy, and harmonious working environment.
Safety Production
| Work Safety Governance
Structure
Salubris strictly complies with laws and
regulations such as the Work Safety Law
of the People's Republic of China, and
has formulated internal policies including
the HSE Management Measures and the
Environmental, Occupational Health and
Safety Management System Manual. A
Group Work Safety Committee has been
established as the central decision-making
body, with each organization establishing
its own sub-committee. Dedicated safety
management departments have been set up
and staffed with full-time safety professionals.
This comprehensive safety governance
framework covers all company premises and
extends to all full-time employees, part-time
employees, contractors, suppliers, and other
relevant stakeholders. | Work Safety Management System
| Accountability Mechanism The Company has built a comprehensive safety management system covering risk control, emergency response,
compliance review, and all-staff communication, effectively achieving dynamic risk prevention and control and efficient
emergency response of unexpected incidents, ensuring continued compliant operation. We continuously advance the
We have established a management-
digitalization of HSE management by developing a unified information platform that integrates core modules such as
level safety accountability mechanism,
risk grading and control, hazard identification and rectification, work permit management, safety training, occupational
incorporating safety and health performance
health records, and contractor management. Relying on a unified data foundation, the system achieves standardized
indicators into the performance appraisal
collection of safety indicators, improving data completeness, accuracy, and auditability.
and compensation-linked system for
management personnel, thereby reinforcing During the reporting period, the Company's work safety management system received external recognition, with the
primary safety responsibilities at all levels. Bao'an, Shandong, and Suzhou plants all obtaining Level 3 Work Safety Standardization certification.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 51
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Salubris Safety Management Mechanism
■? Conduct hazard identification at work sites quarterly, establishing risk graded control ledgers; organize a comprehensive risk re-evaluation
Safety Risk Assessment
annually to ensure dynamic effectiveness of risk identification.
■? Conduct comprehensive reviews of health and safety management situations at all operating locations semi-annually, forming HSE supervision
Safety Compliance Review
reports and HSE dynamic review reports, ensuring all operating locations operate safely and compliantly.
■? Hold annual work safety committee meetings to ensure deep participation of management layers, union representatives, and employee
representatives in safety matter decision-making and discussion.
■? Each branch convenes regular monthly work safety committee meetings, chaired by the head of the respective institution and attended by
Regular Communication
department heads from safety management, production operations, equipment maintenance, and other relevant functions, alongside employee
representatives. Through this standardized monthly communication mechanism, safety directives are promptly cascaded to frontline teams,
ensuring the effective execution of safety decisions and corrective action plans.
■? Launch HSE information management platform, supporting employees to report unsafe behaviors, accident hazards, and near-miss events,
Digital Enabled Management
rewarding those who actively report.
■? Strictly implement occupational health and safety control requirements during contractor entry and cooperation signing, audit partner safety
Contractor Safety Requirements qualifications, and include safety control clauses in cooperation contracts. Carry out comprehensive safety training for all contractor personnel,
with a training coverage rate of 100% for contractors.
Salubris Safety Production Indicators
| Emergency Management Indicator Unit 2025
The Company attaches great importance to emergency management, Lost Workdays Due to Work Injuries days 97
formulating the Accident Reporting and Investigation Disposal Procedures, incidents per 200,000
Total Recordable Incident Rate (TRIR) 0.0970
clarifying comprehensive emergency plans and special disposal schemes working hours
for fire, mechanical injury, chemical leakage, etc. We regularly organize incidents per 200,000
Lost Time Injury Rate (LTIR) 0.0970
emergency drills for scenarios such as fire, electric shock, hazardous working hours
chemicals leakage, poisoning, and suffocation, completely retaining drill incidents per 200,000
Near-miss Report Rate 98
records and rectification tracking archives, continuously improving the working hours
capabilities of emergency response. Hazard Rectification Rate % 99.66
Contractor Lost Time Injury Accident Events incidents 0
The Company sets the occupational health and safety goal of "zero casualty Work Injury Insurance Investment Amount RMB 10,000 301
accidents, zero occupational disease", and sets quantitative indicators Work Injury Insurance Coverage 10 persons 3,936
around it to promote goal implementation. During the reporting period, no
serious work-related casualties or occupational diseases occurred among
both employees and contractors, with 97 workdays lost due to work-related
injuries. The number and rate of work-related fatalities were zero in 2023,
purchases accident insurance for them.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 52
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Salubris Occupational Health and Safety Training Indicators
Workplace Safety Training
Indicator Unit 2025
The Company has formulated an
annual occupational health and Total Person-Times of Occupational Health and Safety Training person-Times 35,392
safety (OHS) training plan, delivering
routine safety training to internal
Total Duration of Occupational Health and Safety Training hours 44,770
employees, contractors, and suppliers.
The training covers safe work
Total Sessions of Occupational Health and Safety Training times 861
practices and the management of
high-risk operations, including hot
work. For newly hired employees in Total Sessions of Occupational Health and Safety Training Conducted for Contractors times 158
production positions, the Company
strictly implements the three-level Covered Number of Contractors for Occupational Health and Safety Training persons 1,754
safety education—factory level,
workshop/department level, and Coverage Rate of Occupational Health and Safety Training for Contractors % 100
team level—to ensure that employees
master job-specific risk identification Total Training Hours for Contractors hours 978
and emergency response skills before
working independently. Certification Rate for Special Operations Personnel % 100
| Safety Production Cultural Activities
Salubris continuously promotes safety production culture construction, creating an
all-staff participatory safety culture atmosphere through diversified publicity activities.
The Company regularly holds themed activities such as Safety Production Month and Fire
Prevention Month, publishes the Salubris HSE Culture Knowledge Manual and the Employee
HSE Manual, pushes safety concepts via safety culture columns, thematic posters, and
new media platforms; synchronously carries out publicity of "Top Ten Safety Concepts" and
"Top Ten Life-Saving Rules," organizes safety knowledge competitions and emergency skill
drills, strengthening employee safety awareness and emergency response capabilities.
The Company establishes a positive incentive mechanism, annually selecting "HSE Annual
Figures" "Safety Guardians" and other advanced models, encouraging employees to
actively report unsafe behaviors and near-miss events, organize HSE-themed expert
activities safety promoting management transformation from passive response to active
prevention, effectively safeguarding employee life safety and production operation stability.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 53
Implementing Compliant Employment Empowering Employee Growth Unlocking Employee Potential Ensuring Health and Safety
Salubris Occupational Health Management Measures
Occupational Health Occupational Health Examinations
Salubris strictly complies with ■? Pre-employment occupational health examination: Newly recruited personnel and transferred personnel must pass occupational health
laws and regulations such as
checks before engaging in jobs contacting occupational hazard factors;
the Law of the People's Republic ■? Periodic occupational health examination: Regularly organize occupational health checks for employees exposed to occupational hazards
of China on the Prevention
annually;
and Control of Occupational ■? Abnormal handling: Transfer employees discovering occupational contraindications or occupational-related health damage from original
Diseases. The Company has
posts and properly arrange them, inform them truthfully, and require re-examination or medical observation/treatment according to
established and implemented
inspection institution requirements.
internal policies, including the
Occupational Disease Hazard
Hazard Factor Identification and Monitoring Labor Protection Equipment Management
Responsibility Prevention
System, the Occupational
■? Determine and identify dust, noise, high temperature, toxic ■? Regularly distribute labor protection equipment for free.
Protective Equipment
substances, and other hazard factors and points in workplaces, Establish regular quality inspection and maintenance systems
Management System, the
conducting regular detection and evaluation according to for special protective equipment such as safety helmets,
Occupational Hazard Monitoring
occupational hygiene management standards. insulating protective equipment, and gas masks; prohibit use
and Evaluation Management
of unqualified or invalid equipment.
System, and the Occupational
Hazard Accident Handling and
Reporting System. The Company Job-specific Training Implementation of the "Three Simultaneities" system
has also built a comprehensive
employee health protection ■? Employees in occupational disease risk posts participate in ■? Strictly implement the "Three Simultaneities" system for
system covering the full business
occupational safety education training for no less than 20 occupational disease prevention facilities in construction
chain to consolidate employees’
hours annually. Training content covers occupational hygiene projects, ensuring occupational disease prevention facilities
health defenses and safeguard
laws and regulations and standards, basic occupational are designed, constructed, and put into production and use
employees’ occupational health
hygiene knowledge, correct use and maintenance of simultaneously with main projects.
and rights.
protective equipment and personal protective equipment,
emergency rescue measures and basic skills, etc.
In 2025, the regular monitoring coverage
for occupational hazard factors across all
workplaces reached 100%. Both training and
occupational health examination coverage 0 100% 100% 100%
occupational health
for the 964 employees in hazard-risk positions occupational regular monitoring training coverage for
examination coverage
stood at 100%. With no occupational hazard disease incidents coverage for occupational employees in hazard-
for employees in
incidents or suspected cases reported, the hazard factors across all risk positions
hazard-risk positions
Company successfully achieved a "zero workplaces
occurrence" of occupational diseases.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 54
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Greening the Future, Fostering
Ecological Harmony
Salubris always regards green
development as one of the long-
term strategic drivers for enterprise
transformation, comprehensively
promoting low-carbon transformation
and ecological environmental protection.
Through gradually strengthening
climate risk management, improving the
environmental management system,
enhancing resource utilization efficiency,
and deepening circular economy
practices in packaging links, while
promoting high-quality development
of the pharmaceutical industry, the
Company actively fulfills its environmental
RMB 28.63 million responsibilities, jointly building a
sustainable future of harmony between
total expenditure on environmental humans and nature.
management
Multiple sites, including Bao'an Factory,
have obtained ISO 14001 Environmental
major accidents involving violations Management System certification.
of environmental laws or major Bao'an Factory has passed ISO 50001
environmental pollution incidents Energy Management System certification.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 55
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Responding to
Climate Change
Salubris recognizes the impact of
climate change on global public
health and the pharmaceutical
industry, integrating climate action into
corporate strategic decision-making.
The Company has established a
comprehensive climate management
framework aligned with four core
pillars: governance, strategy, risk
management, and metrics and
targets. Through this framework, the
Company is committed to reducing its
operational carbon footprint, driving
green transformation, and supporting
global climate action.
Salubris Climate Change Governance Structure and Responsibilities
Governance
Board of Directors
Salubris has established a three-
level climate governance framework
■? As the highest decision-making body, responsible for approving climate-related strategies,
comprising the Board of Directors, Governance supervising the management effectiveness of climate risks and opportunities, and regularly
Production Center HSE Management Level reviewing the achievement of climate goals.
Group and Business Departments
and Functional Departments. The Production Center HSE Management Group
Board of Directors serves as the
highest-level governing body, ■? As the management body, responsible for formulating climate strategies, goals, and plans,
providing strategic oversight and Management supervising their implementation, evaluating major climate risks and opportunities, and
guidance for all climate-related Level
submitting them to the Board of Directors for deliberation.
initiatives. Through clearly defining
responsibilities and powers at each Business Departments and Functional Departments
level, we strengthen climate change
■? As the execution body, responsible for implementation of climate management, including
management.
Executive formulating action plans, promoting emission reduction projects, monitoring and reporting
Level climate performance, and regularly reporting progress.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 56
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Strategy
Salubris attaches importance to short-, medium-, and long-term physical risks and transition risks brought by climate change, establishing a robust mechanism for risk
assessment and opportunity identification, formulating forward-looking countermeasures for potential risks.
Climate-Related Risk Identification
Impact Potential
Risk Type Risk Description Countermeasure Actions
Period Financial Impact
■? Establish regular facility inspection mechanisms, strengthen key equipment
Extreme weather events
reinforcement and drainage system maintenance;
caused by climate Increase in
Acute Risk ■? Improve extreme weather emergency plans and conduct regular drills; Short-term
change (e.g., floods, operating costs
■? Optimize supply chain layout, implement multi-source supply strategies, establish
typhoons)
Physical key material strategic reserves, enhance supply chain resilience.
Risk
Long-term climate ■? Adopt efficient intelligent air conditioning systems, achieving precise indoor
change causing temperature control, mitigating external climate fluctuations' impact on Medium/ Increase in
Chronic Risk
continuous impacts (e.g., operational stability; Long-term operating costs
extreme heat, droughts) ■? Deepen water resource recycling technologies, promote water-saving processes.
Policy and ■? Establish policy regulation dynamic tracking mechanisms, review compliance Medium/ Increase in
Carbon pricing increases
Legal Risk status, actively seek green credit, tax incentives, and other policy support; Long-term operating costs
Low-carbon energy- ■? Continuously deepen the transformation and upgrading of low-carbon energy-
Technology Medium/ Increase in
saving technology R&D saving technologies to reduce carbon emissions across all links including R&D,
Risk Long-term R&D costs
and transformation trends production, and the supply chain.
■? Continuously deepen green procurement and low-carbon supply chain
Transition
Raw material cost development, advance raw material cost control and energy-saving upgrades Medium/ Increase in
Risk Market Risk
increases across the supply chain, and reduce the procurement and logistics costs of core Long-term operating costs
raw materials.
■? Strengthen the comprehensiveness and accuracy of climate information
Stakeholder attention disclosure, continuously disclose carbon emission data and monitor emission
Reputation Medium/ Decrease in
to company climate reduction goal progress;
Risk Long-term revenue
response performance ■? Regularly communicate with investors, timely reply to their opinions and
suggestions on company climate change-related work.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 57
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Climate-Related Risk Identification
Impact Potential
Risk Type Risk Description Countermeasure Actions
Period Financial Impact
Resource Efficiency
Resource ■? Optimize production process flows, reduce unit product resource consumption, thereby Medium/ Decrease in
Improvement
Efficiency reducing energy and water procurement costs, improving overall operational efficiency. Long-term operating costs
Opportunities
■? Increase the proportion of renewable energy in total energy structure, reduce
Renewable Short/
Clean Energy dependence on fossil fuels, avoid traditional energy price fluctuation risks; Decrease in
Opportunity Energy Utilization Medium-
Utilization simultaneously utilize government subsidy policies for green energy projects, reducing operating costs
Opportunities term
construction and operating costs of clean energy facilities.
■? Conform to global market demand for low-carbon products, meet international
Industry Market Expansion Medium/
emerging markets' "green medicine" access standards, participate in global sustainable Increase in revenue
Development Opportunities Long-term
medical initiatives, enhance market share and brand international influence.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 58
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Risk Management
Salubris integrates climate change risk Climate Change Risk Management Process
management into the Company's comprehensive
risk management framework, establishing a full-
process closed-loop mechanism covering risk Regularly identify potential climate-related risks, integrating climate
identification, assessment, and response. Through factors into existing risk control systems.
strengthening cross-departmental collaboration Risk Identification
and implementing board supervision functions, it
achieves comprehensive management of climate- Grade and classify risk events according to severity and likelihood,
related risks and opportunities. compiling risk reports to provide data support for subsequent
management measure formulation.
Risk Assessment
Metrics and Targets
To supervise and promote the Company's climate Formulate various emergency plans and organize drills, regularly
change work, Salubris sets a series of carbon emission- tracking the implementation effectiveness of climate change risk and
related goals, clarifying emission reduction paths Risk Response opportunity countermeasures.
through quantitative management, building a
sustainable low-carbon operating framework.
Scope 1 Greenhouse Gas Emissions 12
Unit
tCO2e
The Company has established a carbon
reduction target: using 202411 as the baseline Scope 2 Greenhouse Gas Emissions 13 tCO2e 54,689
year, the Scope 1 and Scope 2 greenhouse
gas emission intensity will be reduced by Total Greenhouse Gas Emissions tCO2e 64,586
Greenhouse Gas Emission Intensity tCO2e / RMB million of revenue 14.84
In 2025, the Scope 1 and Scope 2 11 In 2024, our Scope 1 and Scope 2 greenhouse gas emission intensity was 15.9 tCO2e / RMB million of revenue.
greenhouse gas emission intensity 12 Scope 1 greenhouse gas emissions primarily arise from the direct combustion of fuels such as gasoline, diesel, and natural gas. The Scope 1 emissions were quantified in
decreased by 6.7% compared with the accordance with the 2006 IPCC Guidelines for National Greenhouse Gas Inventories, published by the Intergovernmental Panel on Climate Change (IPCC).
baseline year. 13 Scope 2 greenhouse gas emissions mainly originate from purchased electricity and purchased heat. The electricity emission factor is selected from the Announcement
on the Release of 2022 Electricity Carbon Dioxide Emission Factors, jointly issued by the Ministry of Ecology and Environment of the People's Republic of China and the
National Bureau of Statistics. The steam emission factor is calculated on a comprehensive basis in accordance with the Guidelines for Accounting and Reporting of
Greenhouse Gas Emissions from Enterprises in Other Industrial Sectors (Trial) and the 2006 IPCC Guidelines for National Greenhouse Gas Inventories.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 59
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Strengthening Environmental Management
Salubris strictly complies with national environmental The Company has formulated the Emergency
protection regulations, formulating and improving Response Plan for Sudden Environmental
an environmental management system mainly Incidents targeting environmental risks
During the reporting period, In 2025
composed of the Environmental Protection that may arise in production and operation
Management System and the HSE System processes, to effectively prevent and minimize no major accidents
Management Manual. We uphold the environmental
policy of "Harmonious Environment, Achieving
RMB 28.63 million
environmental pollution and losses caused
by sudden environmental incidents. In
violating environmental
laws and regulations and
Sustainable Development", aiming to achieve accordance with the emergency plan, we major environmental
"zero environmental pollution accidents." During total expenditure regularly conduct environmental emergency pollution accidents
the reporting period, our total environmental on environmental drills to ensure timely reporting, rapid occurred.
management investment was RMB 28.63 million, management response and efficient disposal in the event of
mainly including expenditures on operating waste environmental pollution incidents.
disposal, upgrading and maintaining environmental
protection equipment, etc.
The Company builds an environmental management Case Acidic Wastewater spill Emergency Response Simulation Drill
governance architecture composed of HSE Production
Center and each factory, ensuring environmental
management operates in a standardized manner and is
To improve hazardous waste operators'
executed effectively. HSE Production Center is responsible
emergency response capabilities for
for overall management and supervisory deliberation of
hazardous waste leaks, in October 2025,
company environmental matters, regularly evaluating
Salubris organized a simulated acidic
goal execution progress, ensuring environmental
wastewater spill emergency response
management remains coordinated with the Company's
drill. The drill set a scenario where
overall development strategy. Each factory is responsible
an environmental specialist spilled
for implementing specific environmental protection
wastewater en route from transporting
measures, ensuring compliance throughout the
acidic wastewater from the laboratory to
production and operation process.
the hazardous waste warehouse due to
To continuously improve environmental management lack of guardrails on the transport cart and
practices, the Company strictly adheres to ISO 14001 overly sharp turning. On-site personnel
standards, continuously improving the environmental immediately activated the emergency
management system. As of the end of the reporting plan for disposal. After the drill ended,
period, 5 office and production sites, including environmental engineers summarized and
the Bao'an Factory and the Daya Bay Factory, Environmental Management provided corrective action guidance on Acidic Wastewater spill
have obtained GB/T 24001-2016 / ISO 14001:2015 System Certification issues identified during the drill process. Emergency Response Drill Site
Environmental Management System certification. Certificate
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 60
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Practicing Resource Conservation
Salubris values resource management, improving resource utilization efficiency
through optimized resource allocation and full-process management. Meanwhile,
we actively practice the circular economy concept, committed to building a
green and sustainable operation model to achieve coordinated development of
economic and environmental benefits.
Energy Management
Salubris regulates and implements
energy management according
to systems such as the Energy
Management Manual and the
Energy Management Policy, Goals,
Scheme Control Procedures.
The Company formulates
special energy monitoring plans,
continuously summarizing
data monthly and conducting
comparative analysis, ensuring
real-time rectification when
abnormalities are detected. In
certification.
Energy Management System
Certification Certificate
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 61
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Energy Management Measures
■? Optimize Blower Systems: Assess environmental blower air volume
requirements, replacing original blowers with low-power, high-efficiency
equipment, saving approximately 130,000 kWh of electricity annually.
■? Upgrade Sterile Workshop Refrigeration Systems: Replace sterile
workshop chillers, improving refrigeration energy efficiency ratios,
effectively reducing electricity consumption required to maintain sterile
environments, saving approximately 480,000 kWh of electricity annually.
■? Strengthen High-Voltage Electrical O&M: Entrust third parties to conduct
preventive testing and maintenance for factory transformers and other
high-voltage electrical equipment, improving electricity usage safety
while reducing power loss.
■? Deepen Energy Management Digitalization: Implement energy
management systems, achieving online collection of water, electricity,
gas, and steam data, promoting management model transformation
from manual statistics to trend analysis and alarm tracing.
■? Promote Fuel Structure Optimization: Introduce biogas to replace natural
gas in RTO (Regenerative Thermal Oxidizer) systems, reducing fossil
energy consumption and lowering carbon emissions.
■? Boiler Waste Heat Recovery: Recover steam condensate and boiler flue
gas waste heat to boilers, achieving resource recycling and reducing
resource waste.
■? Chiller Unit Update and Transformation: Eliminate screw chiller units, use
magnetically levitated chillers with high refrigeration efficiency, reducing
electricity consumption.
■? Optimize Cooling System Operation Modes: Transform cooling systems
from constant frequency operation to on-demand automated control,
reducing cooling losses and lowering electricity consumption.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 62
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Case Energy Monitoring and Management System Project | Clean Energy Usage As of December 31, 2025
The Company explores the broader
application of green energy in
manufacturing processes, promoting million kWh
factory clean energy retrofitting. In July
Salubris launched the energy monitoring and management system cumulative clean electricity
project, aiming to replace traditional manual meter-reading generated by the Company's PV
generation projects were successively
processes. Building upon existing systems, the project established an projects
completed and connected to the
online monitoring platform for the automated collection, centralized
grid at the Daya Bay and Huizhou
management and intelligent analysis of electricity, steam, and
factories. The Company’s PV projects tonnes
other energy data. The project has completed the connection and
make use of factory rooftops to install
commissioning of 38 electricity meters and 16 steam meters, with data reducing carbon dioxide emissions
the photovoltaic system under a self-
upload success rates reaching 99.8%. by approximately
generation and self-consumption
The project improved energy consumption data accuracy from 91% model, with generated clean electricity
to 99.6%, reducing manual recording errors and omissions. Abnormal prioritized for factory production and
alarm response times shortened from 4.5 hours to 12 minutes; during
trial operation, energy waste losses of approximately RMB 27,000
supporting facilities. Projects are
equipped with intelligent photovoltaic
were successfully avoided, effectively reducing unnecessary energy monitoring systems that enable real- Currently, the Company has set clear
consumption. time monitoring of power generation energy consumption goals: with 202414
efficiency and equipment operation as the base year, energy consumption
status, ensuring stable and safe intensity will decrease by 50% by 2023.
operation of the stations.
Energy Usage
Indicator Unit 2025
Natural Gas m? 4,466,810
Direct Energy
Gasoline tonnes 21
Consumption
Diesel tonnes 3
Purchased
Indirect Energy MWh 73,503
Electricity
Consumption
Purchased Heat GJ 138,615
tonnes of standard coal
Comprehensive Energy Consumption 19,739
equivalent
Comprehensive Energy Consumption tonnes of standard coal
Intensity equivalent /RMB million of revenue
Energy Monitoring Management System
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 63
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Water Resource Management
Salubris strictly complies with laws and regulations such as the Water Law of the People's Republic of China and Water Resource Management Measures
the Water Pollution Prevention and Control Law of the People's Republic of China, systematically advancing water
conservation management and water resource protection work. Following national standards, the Company regularly ■? Optimize Injection Water Systems: Under
conducts water risk monitoring and assessment. This process identifies potential risks spanning from water source strict guarantee of water quality safety,
supply and production processes to final discharge, allowing us to formulate differentiated strategies and significantly streamline and optimize factory injection
improve water resource risk management capabilities. The Company takes "water resource recycling rate" and "total
water processes, reducing consumption,
water consumption" as core control goals, continuously deepening efficient water resource utilization.
estimated to save approximately 2,418
tonnes of steam annually.
■? Upgrade Automated Control Systems:
Complete automatic control upgrades for
towers, replacing elevated manual valves
throughout the plant with electric automatic
valves, and implementing load automatic
regulation transformations for three water
systems, achieving precise water supply and
high-efficiency energy saving.
■? Implement Water Resource Recycling:
Establish concentrated water and chilled
water recovery monitoring and tracking
mechanisms and promote reuse, effectively
reducing fresh water consumption, forming
stable water-saving benefits.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 64
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Case Public System Automatic Control Energy Saving
Upgrade Project
In June 2025, Shandong Factory completed
intelligent transformation of five major
public systems in the factory area. The
project implemented automatic control for
towers, upgraded manual valves to electric
valves, achieved automatic load regulation
and chiller interlock control for three water
systems, and integrated them into a unified
access to centralized monitoring platform.
The project achieved significant results,
realizing a comprehensive energy saving
rate of 32%, saving approximately 276,000
kWh of electricity annually, reducing
carbon emissions by approximately 148.1
tonnes, and saving energy consumption
costs of nearly RMB 200,000, achieving
dual improvements in environmental and Public System Intelligent
economic benefits. Transformation
Water Resource Usage15
Indicator Unit 2025
Total Water Consumption tonnes 848,190
tonnes/RMB million of
Total Water Intensity 194.87
revenue
Water Withdrawal Volume tonnes 779,914
Water Consumption Volume tonnes 191,819
Water Resource Recycling Volume tonnes 68,276
Industrial Water Reuse Rate % 8.75
Volume=Water Consumption Volume+Total Wastewater Discharge
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 65
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Circular Economy
Salubris integrates green packaging concepts into its product full-lifecycle
management, and is committed to building a sustainable packaging system
through source reduction, material innovation, and closed-loop recycling, thereby Case Reducing Inner Packaging Waste
comprehensively promoting intensive resource utilization and circular regeneration.
To effectively reduce production cost waste caused by inner packaging
waste, in January 2025, Shandong Salubris carried out a special research
project on reducing inner packaging waste. The project analyzed waste
causes in packaging material usage processes and formulated targeted
improvement measures accordingly. By optimizing management
strategies, the Company extended the validity period of sterilized packaging
materials from 24 hours to 48 hours and adjusted the sterilization limit for
unused packaging materials from "single-use only" to "double-sterilization
permitted." Practice verification confirmed significant results. Practical
verification has demonstrated significant effectiveness of these measures.
The Company compiled and published management regulations such
as "Sterilized Equipment and Items Management Procedures" to provide
guidance for subsequent standardized management.
During the Reporting
Packaging Material Management Measures
■? Upgrade Cold Chain Packaging Specifications: Replace small cold
chain packaging with large-capacity versions, improving single-trip 3,169 tonnes
transportation efficiency; period packaging material usage
■? Promote Circular Replacement Solutions: Replace traditional
cardboard boxes and fiber drums with reusable bulk bags, reducing
disposable packaging material consumption and waste generation; 0.73 tonnes/RMB million
of revenue
■? Adjust Raw Material Packaging Specifications: Adjust product
packaging specifications from 5kg/piece and 10kg/piece to 15kg/piece packaging material usage
and 20kg/piece, reducing PE bag usage.
intensity
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 66
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Promoting Green Case Wastewater Treatment Facility Upgrade and Transformation
Operations
Salubris fully implements green production
concepts in daily operations, systematically
The Huizhou Factory invested
controlling wastewater, waste gas, and solid
RMB 400,000 to purchase a set
waste generated in R&D and manufacturing
of MBR membrane filtration
processes, effectively reducing the
components with a treatment
environmental impacts of operational activities.
capacity of 600 tonnes/day to
solve the problem of decreased
treatment efficiency caused by
Wastewater Management aging original MBR membranes,
replacing and updating old MBR
Salubris strictly executes water pollutant membranes in the wastewater
emission standards and key pollutant total system, further guaranteeing
quantity control requirements, designing wastewater treatment effluent
water supply and drainage systems quality.
according to the principle of "separation
of clean and dirty water, rain and sewage
separation, and recycled water usage," Wastewater Treatment Facility Upgrade
establishing sewage outlets in accordance
with regulations, ensuring stable and
compliant wastewater discharge. The
Company continuously optimizes wastewater
treatment processes, enhancing wastewater Wastewater Discharge
treatment efficiency.
In terms of monitoring management, Indicator Unit 2025
wastewater discharge relies on a
combination of automatic monitoring, routine Total Wastewater Discharge tonnes 588,096
patrols, and regular external monitoring,
perfecting wastewater end monitoring, Total Wastewater Pollutant Discharge tonnes 98.46
accurately grasping wastewater discharge
concentration changes, timely identifying
Chemical Oxygen Demand (COD) tonnes 94.82
potential non-compliance risks, ensuring
all factories' wastewater end discharge
fully meets standards. Meanwhile, we apply Ammonia Nitrogen tonnes 3.55
on-site high-temperature thermal sterilization
technology, effectively killing pathogens and Total Phosphorus tonnes 0.09
reducing environmental risks.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 67
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Waste Gas Management
Salubris continuously optimizes (LDAR) plans are regularly conducted,
atmospheric pollution control and annual third-party airtightness
checks are commissioned, effectively Case Waste Gas Incineration System
facilities, strengthening the waste
gas management system. Classified controlling dispersion risks. In 2025, the
collection and efficient treatment are Company's organized volatile organic
implemented for process waste gases, compounds (VOCs) emissions decreased
The Shandong Factory invested RMB
ensuring compliant discharge. For by approximately 1 tonne compared
fugitive emissions, equipment sealing to 2024, and fugitive VOCs emissions
Regenerative Thermal Oxidizers (RTO)
is improved, Leak Detection and Repair decreased by approximately 3.5 tonnes.
with a treatment capacity of 50,000
cubic meters/hour, further improving
the factory's high-concentration,
complex-component organic waste gas
Waste Gas Management Measures governance efficiency, solidifying the
foundation for stable waste gas compliant
During the Reporting ■? The Company currently has 3 sets of discharge. After the system entered
operation, it formed complementarity
RTO (Regenerative Thermal Oxidizers)
with existing existing scrubbing processes
and multiple sets of activated carbon governance processes, achieving a
adsorption systems. By completing system purification efficiency of over
inspection and transformation of 99%, significantly enhancing the factory's Waste Gas
the No. 1 RTO unit, overall waste gas comprehensive waste gas governance
Incineration System
treatment capacity was improved; capabilities.
the Company's organized
volatile organic compounds simultaneously, operation strategies
(VOCs) emissions decreased are optimized to improve treatment
by approximately efficiency and reduce VOCs emissions;
Waste Gas Discharge Data
■? Strictly implement regular activated
carbon replacement systems, Indicator Unit 2025
guaranteeing adsorption governance
Total Waste Gas Discharge m? 1,176,758,474
effects, ensuring continuous waste gas
compared to 2024, and fugitive
compliant discharge;
VOCs emissions decreased by Particulate Matter tonnes 1.59
approximately ■? Strengthen supervision and
Nitrogen Oxides tonnes 6.97
maintenance of workshop waste gas
tonnes. collection and pretreatment facilities,
Sulfur Oxides tonnes 0.78
regularly conducting special training
to ensure stable facility operation. Volatile Organic Compounds (VOCs) tonnes 11.93
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 68
Responding to Climate Change Strengthening Environmental Management Practicing Resource Conservation Promoting Green Operations
Biodiversity Protection
Salubris strictly complies with the Forest
Waste Management Law of the People's Republic of China,
the Environmental Impact Assessment
Salubris formulates and improves the Hazardous In 2025, the Company conducted regular targeted
Law of the People's Republic of China,
Waste Management System, clarifying full- HSE inspections. Through on-site verification of record
and international biodiversity protection
process control requirements for classification, ledgers and inspection of temporary storage facilities,
initiatives, integrating the minimum
storage, and compliant disposal management. the Company comprehensively identified potential
disturbance principle into site selection,
The Company adopts a combined mode of hazardous waste risks, ensuring that hazardous waste
operations, and the entire supply chain
"on-site storage" and "entrusted certified third- management strictly complied with national laws and
lifecycle. In terms of spatial planning, all
party disposal," implementing strict control to regulations and the Company's internal standards,
company R&D bases and production
effectively prevent secondary pollution risks during thereby effectively reinforcing environmental safety
factories are scientifically sited to avoid
disposal processes. safeguards.
natural protected areas and ecological
red line zones, ensuring they are far from
biodiversity-sensitive areas to eliminate
destruction of original vegetation and
ecosystems at the source. Meanwhile,
During the Reporting we strictly observe ethical standards by
resolutely prohibiting the use of protected
Total non-hazardous Non-hazardous waste Total hazardous Hazardous waste animals in scientific experiments,
waste intensity waste intensity and establish rigorous sustainability
evaluation mechanisms in the raw
material procurement process, refusing
tonnes/RMB million of revenue
tonnes
tonnes/RMB million of revenue
to use rare and endangered plants
and animals as raw materials and fully
tonnes transitioning to environmentally friendly
alternative solutions.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 69
Deepening Inclusive Healthcare Building a Better Society Together
Serving Society, Enriching
Lives
Salubris actively fulfills corporate social
responsibilities, continuously improving
medical accessibility, delivering
high-quality medical resources to
grassroots and underdeveloped
regions. Meanwhile, we carry out
diversified public welfare charity
activities, effectively improving
livelihood well-being, building a social
value ecosystem
marketed drugs have been Annual total charitable donation Cumulative annual service hours
included in the NRDL amount
We Commit:
Oriented towards unmet clinical needs
RMB million
Oriented towards creating social value
Covering more than 20,000 With approximately 200 Cumulative annual value of
hospitals nationwide employees and volunteers pharmaceuticals donated for public
participating in volunteer services welfare was approximately RMB 7.18 million
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 70
Deepening Inclusive Healthcare Building a Better Society Together
Deepening Inclusive care medication accessibility to ensure
equitable access to high-quality drugs
Healthcare across medical institutions at all levels.
As of the end of the reporting period, 32
During the Reporting
out of our 38 marketed drugs have been
Salubris always adheres to the mission
included in the NRDL.
of "improving patients' lives through
exceptional medicines," improving
access to medicines and affordability 32
through fair pricing, optimizing Promoting Access to marketed drugs have been
grassroots drug supply chain systems, included in the NRDL.
etc., aiming to eliminate regional and Medicines
socioeconomic disparities and bring Salubris continues to optimize
high-quality medical resources to its pharmaceutical supply chain
patients worldwide. system, dedicated to enhancing the
continuous accessibility of medicines
in resource-constrained regions.
As of the end of the reporting
Fair Pricing The Company has established a
multi-channel distribution network period , our extensive commercial
Salubris strictly complies with the integrating "in-hospital, out-of- reach covered over
Price Law of the People's Republic of hospital, and e-commerce" channels.
China and drug price management By expanding its first- and second-
regulations, actively building tier distributor networks, it effectively
differentiated product pricing strategies covers grassroots and county-level
for the domestic market, ensuring markets, while vigorously developing
equitable accessibility of medical "dual-channel" pharmacies and
resources in regions with different provincial-level administrative
DTP (Direct-to-Patient) pharmacies.
economic development levels. regions
Simultaneously, we are actively
In the domestic market, the expanding into new retail models,
Company actively aligns with
national medical insurance reform
collaborating with major e-commerce
platforms such as JD.com, Alibaba, 20,000+
policies. By participating in insurance and Meituan, as well as the top 100 hospitals
negotiations, it facilitates the inclusion national pharmacy chains, to improve
of innovative drugs in national and local medicine delivery efficiency in remote
reimbursement lists, thereby reducing areas and enhance convenience for
patient out-of-pocket costs and patients purchasing medications.
alleviating medication burdens.
As of the end of the reporting period, 100,000+
Meanwhile, the Company supports the Company has covered over 20,000
retail pharmacies
adjustments to the National Essential hospitals and more than 100,000 retail
Medicines List and centralized pharmacies across over 30 provincial
procurement policies, optimizing primary regions in China.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 71
Deepening Inclusive Healthcare Building a Better Society Together
Case Carrying Out Medical Personnel Training, Empowering Clinical Level Improvement
Promoting Access to
Healthcare Technology
Salubris is committed to
breaking down information
barriers and strengthening the The Company, in collaboration with the China Medical Foundation, launched the "Non-Dialysis-Dependent
capacity building of medical (NDD) Anemia Screening Registration and Education Special Project." This initiative provides ongoing training
staff in grassroots and general for nephrologists and nurses nationwide. The curriculum covers screening standards for anemia in non-dialysis
hospitals. Through collaboration chronic kidney disease (CKD), individualized management of hemoglobin (Hb) targets, and standardized clinical
with healthcare organizations at application of EnNaLuo, complemented by practical instruction on a digital screening system.
all levels, industry associations,
and public welfare foundations, Additionally, the Company partnered with Beijing United Heart Foundation, under the guidance of the
the Company aims to achieve Cardiovascular Disease Branch of the Chinese Medical Association, carrying out chronic disease standardized
inclusive sharing of diagnostic and diagnosis and treatment public welfare training, providing comprehensive empowerment for cardiovascular,
treatment technologies. nephrology, geriatric, and general practitioners, promoting overall significant advancement of clinical diagnostic
and treatment levels.
Medical Personnel Training Site
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 72
Deepening Inclusive Healthcare Building a Better Society Together
Case Collaborating with the Chinese Medical Doctor Association and the China Health Promotion
and Education Association to strengthen capacity building for grassroots medical staff
In 2025, Salubris partnered with the Chinese Medical Doctor Association
and the China Health Promotion and Education Association to launch
the "Excellent General Practitioner Training Program" and the "Benchmark
Community Visit Project." Leveraging diverse formats such as on-site
visits to benchmark communities, lectures on the latest guidelines,
scenario-based workshops, case simulations, and community health
clinics, the initiative aims to enhance the comprehensive chronic
disease management capabilities of grassroots medical personnel,
particularly key physicians. This effort injects momentum into
accelerating the turning point in cardiovascular disease prevention and
control across China.
Enhancing Chronic Disease Screening and Equitable Access to Health Services
Salubris consistently regards the improvement of public health and well-being as a core responsibility. The company is
dedicated to advancing early screening and diagnosis of chronic diseases and ensuring inclusive, equitable access to health
services, contributing to the development of a health protection network that reaches grassroots communities.
Case Launched World Hypertension Day Community Health Clinic Initiative to Support
Grassroots Chronic Disease Prevention and Control
On May 17, 2025, in observance of the 21st World Hypertension Day,
Salubris partnered with Shenzhen's healthcare system and multiple
hospitals to launch a community outreach initiative under the theme
"Stable blood pressure morning and night is true blood pressure control."
Covering seven districts across Shenzhen, the initiative brought together
eight hospitals at the municipal level or above and nearly 100 medical
experts to conduct 11 free health screening and consultation sessions.
More than 2,000 residents received professional medical consultations
and services. The campaign educated the public on hypertension
prevention, promoted early screening, diagnosis, and treatment, raised
awareness of morning and evening blood pressure monitoring, extend
high-quality healthcare resources to grassroots communities, strengthen
primary-level chronic disease prevention and management, and support Free medical consultation site
the Healthy Shenzhen and Healthy China initiatives.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 73
Deepening Inclusive Healthcare Building a Better Society Together
Building a Better Society Together Case
Carrying Out "EnNaLuo" and "Osteoporosis" Special
Drug Assistance Projects
Salubris regards public welfare charity as an important component of the
Company's sustainable development strategy. Closely aligning with the "Healthy
China" and "Rural Revitalization" national strategies, the Company focuses on Salubris operates "EnNaLuo" and "Osteoporosis" special drug assistance
medical health and rural revitalization, actively fulfilling social responsibilities. projects on an ongoing basis, giving free donated drugs to qualified
In 2025, Salubris's total charitable donation amount reached RMB 27.1 million, renal anemia and osteoporosis patients, effectively alleviating patients'
mobilizing nearly 200 employees and volunteers to participate in volunteer services, economic burdens, guaranteeing patients' continuous standardized
accumulating service hours of 1,965 hours. treatment, synchronously carrying out grassroots medical personnel
capacity-building support, helping improve grassroots medical service
quality and efficiency.
Medical Donations
Drawing on its robust R&D and manufacturing capabilities, Salubris has established
a systematic charitable drug donation program. The Company regularly donates
essential medicines to primary healthcare facilities in rural areas and patients in
underserved regions. The Company has implemented long-term targeted medical
aid programs in Guangdong, Guangxi, Xinjiang, Sichuan, Tibet, Hunan, and other
regions across China. In 2025, cumulative donated public welfare drug value
reached approximately RMB 7.18 million.
At the same time, the Company organized physician volunteers to travel to rural
areas for free chronic disease clinics, simultaneously distributing complimentary
medications. This initiative specifically supplements therapeutic drugs at township
Case Emergency Drug Aid for Myanmar
health centers, effectively alleviating the medication burden on grassroots Earthquake Victims
communities and addressing supply gaps in local medical institutions. By
implementing multiple measures, the Company has expanded the coverage of
high-quality medicines extending to remote areas, thereby significantly improving
medication accessibility for grassroots populations. Responding to national calls, we
actively participated in disaster
During the Reporting Period relief material assistance actions.
In March 2025, Salubris provided
RMB million RMB million international humanitarian
Salubris's total charitable donation cumulative donated public welfare assistance by donating anti-
amount reached drug value reached approximately infective medicines worth more
than RMB 2 million to communities
affected by the earthquake in
Myanmar, supporting post-disaster
with approximately 200 employees hours disease prevention and control
Disaster Area Drug Donation
and volunteers participating in accumulating service hours efforts.
volunteer services
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 74
Deepening Inclusive Healthcare Building a Better Society Together
Rural Revitalization
Addressing essential needs in rural communities, we have implemented a range
of livelihood infrastructure projects, including rural road improvements, upgrades
to village-level health stations, and the development of rural cultural plazas.
These initiatives aim to improve transportation, healthcare, cultural, and sports
infrastructure and contribute to sustainable rural development.
Case Empowering Rural Youth to Co-create a
Sustainable Future
Salubris sponsored the "Second SDGs Rural Sustainable Development
Youth Co-creation Camp”, focusing on rural revitalization and youth
development. By establishing an integrated industry-academia-
research platform, the project inspired university students to contribute
their ideas and empowered rural youth to engage in sustainable
development practices, effectively promoting educational equity and
capacity building in rural areas. For this initiative, Salubris received two
awards from the "Responsibility 100 | CSR China Education List": "Best
Responsible Enterprise Brand" and "Outstanding Youth Impact Project."
Second SDGs Rural Sustainable Development Youth Co-creation Camp
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 75
Appendix I Appendix II Appendix III Our Listening
Appendix I: Key Performance Table
Environmental
Indicator Unit 2025
Greenhouse Gas Emissions
Total greenhouse gas emissions tCO2e 64,586
Scope 1 Greenhouse Gas Emissions tCO2e 9,897
Scope 2 Greenhouse Gas Emissions tCO2e 54,689
Greenhouse Gas Emission Intensity tCO2e / RMB million of revenue 14.84
Emissions
Total wastewater discharge tonnes 588,096
Total wastewater pollutant discharge tonnes 98.46
Chemical Oxygen Demand (COD) tonnes 94.82
Ammonia nitrogen tonnes 3.55
Total phosphorus tonnes 0.09
Total waste gas discharge m? 1,176,758,474
Particulate matter tonnes 1.59
Nitrogen oxides tonnes 6.97
Sulfur oxides tonnes 0.78
Volatile organic compounds (VOCs) tonnes 11.93
Total non-hazardous waste tonnes 1,264
Non-hazardous waste intensity tonnes/RMB million of revenue 0.29
Total hazardous waste tonnes 4,915
Hazardous waste intensity tonnes/RMB million of revenue 1.13
Energy Consumption
Natural gas m? 4,466,810
Gasoline tonnes 21
Diesel tonnes 3
Purchased electricity MWh 73,503
Purchased Heat GJ 138,615
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 76
Appendix I Appendix II Appendix III Our Listening
Indicator Unit 2025
Comprehensive energy consumption tonnes of standard coal equivalent 19,739
Comprehensive energy consumption intensity tonnes of standard coal equivalent/RMB million of revenue 4.53
Total water consumption tonnes 848,190
Total water intensity tonnes/RMB million of revenue 194.87
Water withdrawal volume tonnes 779,914
Water consumption volume tonnes 191,819
Water resource recycling volume tonnes 68,276
Industrial Water Reuse Rate % 8.75
Packaging Material Usage tonnes 3,169
Packaging Material Usage Intensity tonnes/RMB million of revenue 0.73
Social
Indicator Unit 2025
Product Quality and Safety
Commercialized Product Release Pass Rate % 100
Market Supervision Sampling Inspections Pass Rate % 100
Product Quality Training Coverage Rate % 100
Number of Product Recalls / 0
Percentage of Products Subjected to Recall for Health and Safety Reasons % 0
Technological Innovation
R&D Investment Amount RMB hundred million 12.66
R&D Investment as a Percentage of Annual Revenue % 29.10
Number of R&D Personnel persons 827
Percentage of R&D Personnel % 20.23
Patent Application Filed Count items 241
Among Which: Invention Patent Application Filed Count items 226
Patent Grant Count items 63
Among Which: Invention Patent Grant Count items 56
Cumulative Valid Patent Grant Count items 392
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 77
Appendix I Appendix II Appendix III Our Listening
Indicator Unit 2025
Customer Service
Total Customer Complaints times 67
Major Complaint Event Count times 0
Customer Complaint Processing Rate % 100
Supplier Management
Number of Suppliers / 2,594
Mainland China / 2,584
Number of Suppliers by Region
Hong Kong, Macao, Taiwan and Overseas / 10
Number of Key Suppliers / 308
Suppliers Certified by ISO 14001 System / 186
Suppliers Certified by ISO 45001 System / 169
Supplier Certification
Suppliers Certified by ISO 9001 System / 293
Suppliers Certified by Other Certifications / 130
Suppliers Using Eco-friendly Materials and Circular Packaging / 21
Overdue Payments to Small and Medium-sized Enterprises RMB 10,000 0
Employee Employment
Total Number of Employees persons 4,087
Male persons 2,114
By Gender
Female persons 1,973
By Age Group 30-50 years old (inclusive) persons 2,751
Above 50 years old persons 165
Doctoral Degree or Above persons 68
Master's Degree persons 427
By Education Level
Bachelor's Degree persons 1,861
Associate Degree or Below persons 1,731
General Employees persons 3,632
By Job Level Middle Management persons 439
Senior Management persons 16
Mainland China persons 4,055
By Region
Hong Kong, Macao, Taiwan and Overseas persons 32
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 78
Appendix I Appendix II Appendix III Our Listening
Indicator Unit 2025
Han Ethnicity persons 3,834
By Ethnicity/Race Ethnic Minorities persons 215
Overseas persons 38
Production persons 1,154
Technical persons 827
By Profession
Sales persons 1,698
General persons 408
Full-time Employees persons 3,940
By Employment Type
Non Full-time Employees persons 147
Female in Junior Management persons 117
Female in Middle Management persons 115
Female in Senior Management persons 5
Employee Diversity
Female in STEM-related Positions persons 698
Female Managers in Revenue-generating
persons 138
Positions
Total New Hires persons 1,053
Male persons 501
Female persons 552
New Recruitment
Above 50 years old persons 6
Employee Turnover
Turnover Rate % 16
Male Turnover Rate % 17
Turnover Rate By Gender
Female Turnover Rate % 15
Turnover Rate By Age Group 30-50 years old (inclusive) % 13
Above 50 years old % 13
Mainland China % 16
Turnover Rate By Region
Hong Kong, Macao, Taiwan and Overseas % 0
General Employees % 16
Turnover Rate By Job Level Middle Management % 13
Senior Management % 0
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 79
Appendix I Appendix II Appendix III Our Listening
Indicator Unit 2025
Employee Development
Percentage of Employees Trained % 100
Male persons 2,114
By Gender Training Coverage
Female persons 1,973
Male % 100
Gender Training Percentage
Female % 100
General Employees persons 3,632
By Job Level Training Coverage Middle Management persons 439
Senior Management persons 16
General Employees % 100
By Job Level Training Percentage Middle Management % 100
Senior Management % 100
Total Annual Training Hours hours 240,296
Average Training Hours per Employee hours 59
Male hours 62
By Gender Average Training Hours
Female hours 56
General Employees hours 59
By Job Level Average Training Hours Middle Management hours 57
Senior Management hours 18
Number of Employees Under Performance Appraisal or Career Development
persons 3,651
Assessment
Percentage of Employees Under Performance Appraisal or Career Development
% 90
Assessment
Occupational Health and Safety
Number of Work-Related Deaths persons 0
Lost Workdays Due to Work Injuries days 97
Total Recordable Incident Rate (TRIR) incidents per 200,000 working hours 0.0970
Lost Time Injury Rate (LTIR) incidents per 200,000 working hours 0.0970
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 80
Appendix I Appendix II Appendix III Our Listening
Indicator Unit 2025
Near-miss Report Rate incidents per 200,000 working hours 98
Hazard Rectification Rate % 99.66
Contractor Lost Time Injury Accident Events incidents 0
Work Injury Insurance Investment Amount RMB 10,000 301
Work Injury Insurance Coverage persons 3,936
Total Person-Times of Occupational Health and Safety Training person-times 35,392
Total Duration of Occupational Health and Safety Training hours 44,770
Total Sessions of Occupational Health and Safety Training times 861
Total Sessions of Occupational Health and Safety Training Conducted for
times 158
Contractors
Covered Number of Contractors for Occupational Health and Safety Training persons 1,754
Coverage Rate of Occupational Health and Safety Training for Contractors % 100
Total Training Hours for Contractors hours 978
Certification Rate for Special Operations Personnel % 100
Occupational Health Examination Rate of Occupational Disease Risk Post
% 100
Employee
Number of Occupational Disease Risk Post Employees persons 964
Number of Employees Participating in Occupational Health Examination persons 964
Number of Employees with Occupational Disease Incidence persons 0
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 81
Appendix I Appendix II Appendix III Our Listening
Governance
Indicator Unit 2025
Corporate Governance
Number of Board Meetings Held times 9
Director Attendance Rate % 100
Information Security and Privacy Protection
Total Number of Data Security Incidents incidents 0
Total Number of Customer Privacy Breach Incidents incidents 0
Financial Impact of Data Security Incidents RMB 10,000 0
Financial Impact of Customer Privacy Breach Incidents RMB 10,000 0
Percentage of Regular Employees Participating in Information Security Training % 100
Number of Information Security Audits times 2
Community Welfare
Total amount of charitable donations RMB 10,000 2,710
Total hours of participation in charitable activities hours 1,965
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 82
Appendix I Appendix II Appendix III Our Listening
Appendix II: Index of the ESG Code of the Hong Kong Stock Exchange
KPIs Corresponding Chapters
Category: Environment
A1 Emissions
General Disclosure 4.4 Promoting Green Operations
A1.1 The types of emissions and respective emissions data
Key Performance Indicator Table
Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of 4.4 Promoting Green Operations
A1.3
production volume, per facility). Key Performance Indicator Table
Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of 4.4 Promoting Green Operations
A1.4
production volume, per facility). Key Performance Indicator Table
A1.5 Description of emission target(s) set and steps taken to achieve them. 4.4 Promoting Green Operations
Description of how hazardous and non-hazardous wastes are handled, and a description of waste
A1.6 4.4 Promoting Green Operations
reduction target(s) set and steps taken to achieve them.
A2 Use of Resources
General Disclosure 4.3 Practicing Resource Conservation
Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in’ 000s) 4.3 Practicing Resource Conservation
A2.1
and intensity (e.g. per unit of production volume, per facility). Key Performance Indicator Table
A2.2 Water consumption in total and intensity (e.g. per unit of production volume, per facility).
Key Performance Indicator Table
A2.3 Description of energy use efficiency target(s) set and steps taken to achieve them. 4.3 Practicing Resource Conservation
Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency
A2.4 4.3 Practicing Resource Conservation
target(s) set, and steps taken to achieve them.
Total packaging material used for finished products (in tonnes) and, if appropriate, with reference 4.3 Practicing Resource Conservation
A2.5
to per unit produced. Key Performance Indicator Table
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 83
Appendix I Appendix II Appendix III Our Listening
KPIs Corresponding Chapters
A3 The Environment and Natural Resources
General Disclosure 4.2 Strengthening Environmental Management
Description of the significant impacts of activities on the environment and natural resources and
A3.1 4.2 Strengthening Environmental Management
the actions taken to manage them.
Category: Social
Employment and Labor Practices
B1: Employment
General Disclosure 3.1 Implementing Compliant Employment
Total workforce by gender, employment type (for example, full- or part-time), age group and 3.1 Implementing Compliant Employment
B1.1
geographical region. Key Performance Table
B1.2 Employee turnover rate by gender, age group and geographical region.
Key Performance Table
B2: Health and Safety
General Disclosure 3.4 Ensuring Health and Safety
Number and rate of work-related fatalities occurred in each of the past three years including the
B2.1 3.4 Ensuring Health and Safety
reporting year.
B2.2 Lost days due to work injury. 3.4 Ensuring Health and Safety
Description of occupational health and safety measures adopted, and how they are implemented
B2.3 3.4 Ensuring Health and Safety
and monitored.
B3: Development and Training
General Disclosure 3.3 Unlocking Employee Potential
Key Performance Table
The percentage of employees trained by gender and employee category (e.g. senior 3.2 Empowering Employee Growth
B3.1
management, middle management). Key Performance Table
B3.2 The average training hours completed per employee by gender and employee category.
Key Performance Table
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 84
Appendix I Appendix II Appendix III Our Listening
KPIs Corresponding Chapters
B4: Aspect Labour Standards
General Disclosure 3.1 Implementing Compliant Employment
B4.1 Description of measures to review employment practices to avoid child and forced labour. 3.1 Implementing Compliant Employment
B4.2 Description of steps taken to eliminate such practices when discovered. 3.1 Implementing Compliant Employment
Operating Practices
B5: Aspect Supply Chain Management
General Disclosure 2.4 Industrial Synergy and Common Prosperity
B5.1 Number of suppliers by geographical region. 2.4 Industrial Synergy and Common Prosperity
Description of practices relating to engaging suppliers, number of suppliers where the practices
B5.2 2.4 Industrial Synergy and Common Prosperity
are being implemented, and how they are implemented and monitored.
Description of practices used to identify environmental and social risks along the supply chain,
B5.3 2.4 Industrial Synergy and Common Prosperity
and how they are implemented and monitored.
Description of practices used to promote environmentally preferable products and services when
B5.4 2.4 Industrial Synergy and Common Prosperity
selecting suppliers, and how they are implemented and monitored.
B6: Product Responsibility
General Disclosure 2.1 Keeping Quality Commitments
B6.1 Percentage of the total products sold or shipped subject to recalls for safety and health reasons. 2.1 Keeping Quality Commitments
B6.2 Number of products and service related complaints received and how they are dealt with. 2.3 Putting Patients First
B6.3 Description of practices relating to observing and protecting intellectual property rights. 2.2 Focusing on Technological Innovation
B6.4 Description of quality assurance process and recall procedures. 2.1 Keeping Quality Commitments
Description of consumer data protection and privacy policies, and how they are implemented
B6.5 1.4 Information Security and Privacy Protection
and monitored.
B7: Anti-corruption
General Disclosure 1.3 Practicing Business Ethics
Number of concluded legal cases regarding corrupt practices brought against the issuer or its
B7.1 1.3 Practicing Business Ethics
employees during the reporting period and the outcomes of the cases.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 85
Appendix I Appendix II Appendix III Our Listening
KPIs Corresponding Chapters
Description of preventive measures and whistle-blowing procedures, and how they are
B7.2 1.3 Practicing Business Ethics
implemented and monitored.
B7.3 Description of anti-corruption training provided to directors and staff. 1.3 Practicing Business Ethics
Community
B8 Community investment
General Disclosure 5.2 Building a Better Society Together
Focus areas of contribution (e.g., education, environmental issues, labour needs, health, culture
B8.1 5.2 Building a Better Society Together
and sport).
B8.2 Resources contributed (e.g. money or time) to the focus area 5.2 Building a Better Society Together
Climate-related disclosures
Governance Governance 4.1 Responding to Climate Change
Climate-related risks and opportunities 4.1 Responding to Climate Change
Business model and value chain 4.1 Responding to Climate Change
Strategy and decision-making 4.1 Responding to Climate Change
Strategy
Financial position, financial performance and cash flows 4.1 Responding to Climate Change
Climate resilience 4.1 Responding to Climate Change
Financial impacts of climate-related risks and opportunities 4.1 Responding to Climate Change
Risk management Risk management 4.1 Responding to Climate Change
Greenhouse gas emissions 4.1 Responding to Climate Change
Climate-related transition risks 4.1 Responding to Climate Change
Climate-related physical risks 4.1 Responding to Climate Change
Metrics and Targets Climate-related opportunities 4.1 Responding to Climate Change
Not applicable. During the reporting period,
the Company had no specific material capital
Capital deployment expenditure related to climate-related risks and
opportunities, and did not engage in any climate-
related financing or investing activities.
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 86
Appendix I Appendix II Appendix III Our Listening
KPIs Corresponding Chapters
Not applicable. The Company does not currently
Internal carbon prices
use an internal carbon price.
Not applicable. The Company has not yet
Remuneration incorporated climate-related factors into its
remuneration policy.
Not applicable. Industry-based metrics are not
Metrics and Targets Industry-based metrics
applicable to the Company
Climate-related targets 4.1 Responding to Climate Change
Cross-industry metrics: 4.1 Responding to Climate
Change.
Applicability of cross-industry metrics and industry-based metrics
Industry-based metrics are not applicable to the
Company
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 87
Appendix I Appendix II Appendix III Our Listening
Appendix III: Index of the Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen
Stock Exchange—Sustainability Report (For Trial Implementation)
Dimension No. Issues Corresponding Clauses Corresponding Chapters
Environmental
Social
Social 17 Employees Article 50
Sustainability-
Related
Governance
Overview ESG Governance Strengthening Foundation Crafting Medicines with Care Cultivating Talent Greening the Future Serving Society Appendix 2025 Environmental, Social and Governance (ESG) Report 88
Appendix I Appendix II Appendix III Our Listening
Our Listening
Dear Reader,
Greetings! Thank you for reading the 2025 Environmental, Social and Governance (ESG) Report of Shenzhen Salubris Pharmaceuticals Co., Ltd. We highly value and welcome
your feedback on the Company’s ESG management, practices, and disclosure. Your comments and suggestions will serve as important references for us to continuously
improve our ESG management and practices. We look forward to your response!
responsibilities reflected in this Report?
Government & Regulators Shareholders & Investors Customers
Excellent Good Fair Poor
Consumers Employees Suppliers Partners Community the Public
Others (please specify): responsibilities reflected in this Report?
Excellent Good Fair Poor
Excellent Good Fair Poor
Excellent Good Fair Poor
and data disclosed in this Report?
Excellent Good Fair Poor
responsibilities reflected in this Report?
Excellent Good Fair Poor
首页
微信公众号
证券之星APP
